Sensor body for binding and / or condensing and / or detecting analyte in sample

A thermoresponsive polymer scaffold in the sensor body addresses the inefficiencies of existing assays by enabling efficient analyte concentration and detection with high signal strength and purity through reversible expansion and contraction, reducing the need for extensive washing and handling.

JP2024156890AInactive Publication Date: 2024-11-06BLINK AG
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024128808
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-12-29
Filing Date
2024-08-05
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing binding assays require multiple steps, including washing to remove non-specifically bound materials, which can affect signal accuracy and are time-consuming, especially with porous sensor matrices, and homogeneous assays lack high signal-to-noise ratios and efficient protocols.

Method used

A sensor body with a porous polymer scaffold responsive to external conditions, such as temperature, that can reversibly expand and contract, allowing for efficient binding, concentration, and detection of analytes without the need for extensive washing, using thermoresponsive polymers like pNIPAM to enhance signal strength and purity.

Benefits of technology

The sensor body achieves high signal-to-noise ratios and reduces handling requirements by efficiently concentrating analytes, purifying them, and detecting them in a single vessel through temperature cycling, eliminating the need for additional washing steps.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156890000023
    Figure 2024156890000023
  • Figure 2024156890000024
    Figure 2024156890000024
  • Figure 2024156890000025
    Figure 2024156890000025
Patent Text Reader

Abstract

To provide a sensor body for binding and / or condensing an analyte.SOLUTION: A sensor body for binding and / or condensing an analyte includes a porous polymer scaffold and an interstitial pore space in the polymer scaffold. The porous polymer scaffold is composed of a polymer capable of responding to a change in at least one external condition to which the sensor body is exposed, for example, pH, temperature, salt conditions, and the existence or nonexistence of a chemical substance, and one or more capture agents for the analyte adhere to the porous polymer scaffold.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a sensor body for binding and / or concentrating an analyte. Furthermore, the present invention relates to a method for binding an analyte to the sensor body. Furthermore, the present invention also relates to a method for concentrating and / or washing an analyte bound to the sensor body, as well as a method for detecting an analyte in a sample using said sensor body. Furthermore, the present invention relates to a device for binding and / or concentrating and / or detecting an analyte in a sample. [Background technology]

[0002] The most common form of binding assays utilizes binding elements immobilized on a substrate, preferably on microparticles or microspots, that bind the analyte of interest. In a sandwich configuration, a second labeled binding partner is bound to the analyte. Once the unbound label has been removed by some type of washing step, the amount of label bound to the sensor body is detected and quantified. The detected signal indicates the amount of analyte in the sample. The outlined techniques and their variations (competitive binding assays, sandwich capture assays, etc.) are well known [1]. Any binding assay includes the steps of binding the analyte, washing to remove non-specifically bound material, labeling the bound analyte, washing to remove non-specifically bound label, and finally detecting and quantifying the amount of bound label, which can be considered to be indicative of the amount of analyte present in the sample (based on some form of calibration). From a practical point of view, it is highly desirable to reduce the number of steps required to perform a binding assay. Moreover, any washing steps require careful handling. Specifically bound material is removed at the same time as non-specifically bound material. As a result, less analyte-specific signal is detected. Any change in the steps performed is expected to affect the signal and therefore the accuracy of the test assay. Essentially, binding assays can be divided into the categories of heterogeneous and homogeneous assays [2]. The former have the advantage of using relatively simple detection equipment and reagents, whereas the latter result in a simplified workflow with minimal handling steps. In heterogeneous assays, the signal emitted by bound labeled reactants is indistinguishable from that emitted by free labeled reactants. Hence, a separation step is required to distinguish between the two. Typical heterogeneous immunoassays include radioimmunoassays (RIA) and enzyme-linked immunosorbent assays (ELISA). In homogeneous assays, the signal emitted by specifically bound labeled reactants differs from that emitted by free labeled reactants.Homogeneous assays achieve their specificity through the use of specific reagents that allow them to distinguish between the state of label bound to the analyte and the unbound state.

[0003] For assays requiring delicate sensitivity and quantification, heterogeneous assays remain the gold standard [3]. To increase the amount of bound analyte and therefore the signal detected, porous sensor matrices in the form of microparticles with increased binding area have been employed [4]. However, porous materials also require more careful washing to remove nonspecifically bound signal-generating entities. Porous materials require additional time and more liquid volumes compared to solid particles with an essentially flat surface, since the entire surface, including the porous inner part of the sensor body, needs to be exposed to the washing liquid. Also particularly time-consuming is the removal of nonspecifically bound signal-generating entities released by the washing solvent from the porous matrix. This process can be very slow and rather inefficient if relying only on passive diffusion. So far, thermoresponsive polymers have been employed to perform immunoassays, such as using a conjugate of thermoresponsive polymer and antibody to bind with the analyte and an antibody labeled with a second dye to establish a sandwich-like configuration (Auditore-Hargreaves, Monji [5-7]). When the temperature of the solution is set to a temperature higher than the critical solution temperature of the polymer, nonspecific precipitated aggregates are formed in situ due to the induction of a phase change of the polymer. The content of signal attached to the formed particles is proportional to the amount of antigen in the sample. This technique requires the formation of a polymer matrix in situ and / or the precipitation of polymer aggregates, which are difficult to control since they cannot be detected and / or visually recognized before precipitation and are difficult to handle due to their lack of defined dimensions. [Prior art documents] [Non-patent literature]

[0004]

Non-licensed literature 1

Non-licensed Document 2

Non-licensed Document 4

Non-licensed Document 5

Non-licensed Document 6

[0005] Therefore, assays and reagents that foster high signal to background signal and minimal handling requirements are highly desirable.

[0006] Furthermore, there is a need in the art for homogeneous assays that can provide high signal to noise ratios and that do not require costly or time consuming work-up protocols.

[0007] In a first aspect, the present invention relates to a sensor body for binding and / or concentrating an analyte, said sensor body comprising a porous polymer scaffold and an interstitial pore space within said polymer scaffold, said porous polymer scaffold being composed of a polymer that responds to changes in at least one external condition to which said sensor body is exposed, such as pH, temperature, salt conditions, presence or absence of a chemical, and having attached to said porous polymer scaffold one or more capture agents for the analyte.

[0008] In one embodiment, the polymer responsive to a change in the at least one external condition to which the sensor body is exposed is a thermoresponsive polymer, the thermoresponsive polymer being a thermoresponsive polymer having a lower critical solution temperature (LCST polymer), preferably selected from poly(N-isopropylacrylamide) (pNIPAM), poly[2-(dimethylamino)ethyl methacrylate] (pDMAEMA), hydroxypropyl cellulose, poly(vinyl caprolactam) (P(VCL), and polyvinyl methyl ether); or the thermoresponsive polymer is a thermoresponsive polymer having a lower critical solution temperature (LCST polymer), preferably selected from poly(N-isopropylacrylamide) (pNIPAM), poly[2-(dimethylamino)ethyl methacrylate] (pDMAEMA), hydroxypropyl cellulose, poly(vinyl caprolactam) (P(VCL), and polyvinyl methyl ether). The thermoresponsive polymer is a thermoresponsive polymer having an upper critical solution temperature (UCST), and is preferably any one selected from poly(N-acryloylglycinamide) (PNAGA), poly(allylamine)-co-poly(allylurea) and its derivatives, poly(methacrylamide), poly(N-acryloylaspargineamide), poly(N-methacryloylglutamine amide), poly(acrylamide)-co-(acrylonitrile), poly(sulfobetaine), and poly(phosphorylcholine).

[0009] In one embodiment, the responsive polymer, in particular the thermoresponsive polymer, is preferably crosslinked by at least one crosslinking reagent that bridges and interconnects different polymer chains within the polymer, or by providing a substrate, in particular a substantially flat substrate, adjacent to the sensor body and interfacially crosslinking different polymer chains of the polymer to the substrate, in particular to the surface of the substrate. Of note, the at least one crosslinking reagent is preferably not an antibody or an antibody fragment. It is also preferably not an antibody or an antibody fragment that is linked to another antibody, for example directly or via a common or shared antigen. According to an embodiment of the invention, the crosslinking reagent that bridges and interconnects different polymer chains within the polymer is a substance that can react with two or more groups on the polymer. Therefore, it is expected that polymers with reactive side groups such as hydroxyl, amide, or carboxyl are most amenable to crosslinking. Examples of suitable cross-linking agents include acetaldehyde, formaldehyde, N,N'-methylene-bisacrylamide, ethylene glycol dimethacrylate, glycerin triacrylate, divinylbenzene, glutaraldehyde, diglycidyl ether, divinyl sulfone, diisocyanate, epichlorohydrin, phosphoryl chloride, trimetaphosphate, trimethylolmelamine, and polyacrolein.

[0010] In one embodiment, the sensor body has the ability to reversibly assume expanded and contracted states, and preferably when the sensor body is in the expanded state, the interstitial pore space has a volume of at least 50%, preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90% of the total volume of the sensor body. In one embodiment, approximately 10% to 90% of the total volume of the interstitial pore space is not accessible to the analyte but is accessible to a solvent, preferably water.

[0011] In one embodiment, the analyte is a biomolecule selected from nucleic acids, preferably DNA or RNA, nucleotides, oligonucleotides, proteins and peptides, lipids, such as phospholipids, preferably said biomolecule has a size >0.1 kDa, such as 0.5 kDa, preferably >5 kDa, more preferably >10 kDa, even more preferably >50 kDa, or said analyte is a virus or a cell.

[0012] In one embodiment, the pore space of the interstitial space is dimensioned to receive liquid from a liquid sample containing or suspected of containing the analyte.

[0013] In one embodiment, the sensor body is not a core-shell particle.

[0014] In one embodiment, the capture agent is specific for a given analyte and is selected from an antibody, an antibody fragment, an aptamer, a nucleic acid including a spiegelmer, a non-antibody protein capable of specifically binding to the analyte or analyte complex, e.g. a receptor, a receptor fragment, an affinity protein, a chemical moiety such as streptavidin, biotin, Strep-tag®, digoxigenin, dinitrophenol, a nucleic acid tag or a nucleic acid analogue tag, or a similar chemical moiety capable of specifically binding, or D =10 -8 From 10 -15 The hydrophobic structure is selected from a hydrophobic structure capable of specifically binding to an antibody, an antibody fragment, an aptamer, a nucleic acid including a spiegelmer, a non-antibody protein, such as a receptor, a receptor fragment, an affinity protein, such as streptavidin, with an affinity in the range of M, or capable of specifically binding to a hydrophobic molecule or a molecule having a hydrophobic group, preferably said hydrophobic structure having a logD of greater than 2 under the conditions under which said detection of said analyte is carried out.

[0015] The term "logD" as used herein is meant to refer to the logarithm of the distribution coefficient (D), which is the ratio of the concentrations of a compound in a mixture of two immiscible phases at equilibrium. In a preferred embodiment, the term "distribution coefficient" is defined herein as When used herein, the term "partition coefficient" is used synonymously with "partition coefficient". In a preferred embodiment, "partition coefficient" refers to the ratio of the concentration of a compound in a mixture of water and 1-octanol. Typically, such measurements of partition coefficients are performed by any suitable technique known to those skilled in the art. Such suitable techniques include the "shake flask technique" in which the compound in question is dissolved in a given volume of octanol and water, and then the concentration of such compound in each solvent is further measured. Other suitable techniques include high performance liquid chromatography (HPLC). In such HPLC techniques, the partition coefficient (D) and its logarithm can be determined by correlating its retention time with similar compounds with known partition coefficient values.

[0016] In one embodiment, the sensor body is either an isolated particle, preferably freely diffusible, or said sensor body is an immobilized spot on the surface of a substrate.

[0017] In a further embodiment, said sensor body is a coating of a defined area on the surface of a substrate. In this embodiment, if the sensor body is a spot or a coating on the surface of a substrate, the present invention also envisages and encompasses an assembly of said spot and said substrate, or of said coating and said substrate, which assemblies form part of the present invention.

[0018] In one embodiment, the sensor body is an isolated particle, preferably freely diffusible, said isolated particle having a spherical or spherical shape, preferably having a spherical or spherical shape and having clearly defined boundaries that can be observed visually, preferably by microscope or other optical means.

[0019] In one embodiment, the sensor body has an average diameter in the range of 1 μm to 1 mm.

[0020] In one embodiment the sensor body is a spot immobilised on the surface of a substrate, said spot having clearly defined boundaries which can be observed visually, preferably by microscope or other optical means, and preferably has a boundary of less than 1 μm 2 From 1mm 2 , and the thickness of the spots varies depending on the external conditions to which the spots are exposed, and therefore whether the spots are in an expanded or contracted state.

[0021] In one embodiment, the sensor body is a coating of a defined area on the surface of a substrate, in such an embodiment, the coating has a clearly defined boundary that can be observed visually, preferably microscopically, or by other optical means.

[0022] In a further aspect, the present invention provides a method for binding an analyte to a sensor body, comprising the steps of: a) providing, in any order, a sensor body according to the invention as defined above, and an aqueous sample suspected of containing the analyte; b) exposing the sensor body to the aqueous sample, thereby allowing analytes present in the sample to bind to the sensor body and allowing liquid into the interstitial pore space of the sensor body. The present invention relates to a method comprising the steps of:

[0023] When the sensor body is exposed to the aqueous sample, it is preferably subjected to conditions that allow the sensor body to adopt an expanded state that favors binding of any analytes present in the sample to the sensor body and also favors ingress of liquid into the interstitial pore space of the sensor body.

[0024] In a preferred embodiment of the method according to the invention described herein, at least one external condition to which the sensor body is exposed and to which the polymer of the sensor body is responsive is temperature, and the responsive polymer is a thermoresponsive polymer.

[0025] In a further aspect, the present invention relates to a method for concentrating and / or washing an analyte bound to a sensor body, comprising the steps of: c) carrying out the method for binding the analyte to the sensor body as defined above; d) changing the state of the sensor body from an expanded state to a contracted state by changing at least one external condition to which the sensor body is exposed, such as one of temperature, pH, salt concentration, presence or absence of a chemical, thereby forcing out the liquid contained in the interstitial pore space of the sensor body; e) changing the state of the sensor body from a contracted state to an expanded state by changing at least one external condition to which the particles are exposed, such as one of temperature, pH, salt concentration, presence or absence of a chemical, thereby admitting liquid into the interstitial pore space of the sensor body. Including, If the analyte is bound to said particles, steps d) and e) are performed after step c), the analyte being either labeled or unlabeled; wherein steps d) and e) are repeated n times, n being an integer in the range of 1 to 1000, preferably 1 to 500, preferably 1 to 250, more preferably 1 to 100, even more preferably 1 to 50 and more preferably 1 to 40, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 and even more preferably 1 to 20, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0026] In one embodiment, n is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30. When steps d) and e) are repeated n times, with n>1, a very high purity of the analyte may be achieved, i.e. the analyte may be obtained in a very pure form and / or free of contaminants.

[0027] In one embodiment, and / or typically, during the performance of steps c) to e), the sensor body is surrounded by a bulk aqueous solution, e.g. the aqueous sample, and during at least one of steps c) to e), the liquid around the sensor body is exchanged by agitating the bulk aqueous solution. Agitation of the bulk aqueous solution can be achieved by any suitable means, e.g. stirring, shaking, shaking, tapping, or any other mechanical action suitable for achieving movement of the bulk aqueous solution. In one embodiment, the method comprising steps c) and e) is performed with the sensor body (or sensor bodies) and the aqueous sample suspected of containing the analyte contained in a reaction vessel, such as in such an embodiment a reaction vessel, and agitation can be achieved simply by moving, e.g. shaking, the reaction vessel. Without wishing to be bound by any theory, the inventors believe that the repeated combination of steps d) and e) together with the agitation of the bulk of the aqueous solution surrounding the sensor body results in substantial material flow through the porous polymer scaffold and / or the interstitial pore space of the sensor body and / or any capture agent attached to the porous polymer scaffold, thus enabling efficient binding of any analyte to the sensor body. The agitation of the bulk of the aqueous solution surrounding the sensor body results in efficient microscopic liquid exchange around the sensor body, thus contributing to the above-mentioned material flow.

[0028] Furthermore, the repetition of steps d) and e), alone or in combination with agitation of the bulk of the aqueous solution surrounding the sensor body, allows for the method to be carried out in a single vessel, eliminating the need for any transfer steps (e.g., to another environment, e.g., to another vessel).For illustrative purposes, a sensor body after exposure to the aqueous sample suspected of containing an analyte does not need to be removed from the vessel in which exposure occurred in order for concentration of the analyte by the sensor body to occur.

[0029] In a further aspect, the present invention provides a method for detecting an analyte in a sample, comprising the steps of: - carrying out a binding method or a concentration and / or washing method as defined above, wherein the analyte is or will be labelled, either before, during or after binding of said analyte to said sensor body; - detecting said analyte bound to said sensor body by detecting a label bound to said sensor body, preferably in the presence of unbound label. The present invention relates to a method comprising the steps of:

[0030] In an embodiment of the method for detecting an analyte as defined above, this involves the execution of steps a) and b) (→ method for binding an analyte to a sensor body) as defined above. In this specification, the execution of steps a) and b) is sometimes also referred to as the execution of step c), i.e. performing step c) means performing steps a) and b). Then, in some embodiments, the execution of steps d) and e) is carried out (→ method for concentrating and / or washing an analyte bound to a sensor body), such execution can be repeated n times as defined above. Furthermore, the method for detecting an analyte according to the invention finally involves the detection of an analyte bound to said sensor body. To do this, preferably the analyte is or is labeled either before, during or after binding of the analyte to said sensor body. Detection of the analyte is achieved by detecting a label bound to the sensor body. Labeling of the analyte can be achieved by any suitable means, for example via a dye, a labeled antibody, etc.

[0031] According to an embodiment of the invention, the method for detecting an analyte is carried out in a single reaction vessel, i.e. steps a) to e) and the detection step. In one embodiment, such a method is carried out without any washing steps or any steps aimed at removing unbound label. The detectable signal that can be achieved according to the invention does not require the removal of any (unwanted) background signal, e.g. fluorescent background. According to a further aspect, the invention also relates to a device for binding and / or concentrating an analyte, comprising: - a container for receiving a plurality of sensor bodies as defined herein and for receiving an aqueous sample suspected of containing an analyte; - a plurality of sensor bodies as defined herein contained in said container, wherein the polymer scaffold of said sensor bodies is composed of a thermoresponsive polymer; - means for controlling and cycling the temperature in said container; and - optionally, means for mechanically agitating the aqueous sample if present in said container; The present invention also relates to a device including:

[0032] In one embodiment, the device according to the invention comprises: - a sensor body within said container, and an optical detector configured to detect changes in size, appearance, light absorption, light emission and / or fluorescence of said sensor body, if present; Such a change may occur, for example, when an analyte, preferably a labeled analyte, binds to the sensor body. In embodiments where the device also includes a sensor body in the container and an optical detector configured to detect changes in the size, appearance, absorption of liquid, etc. of the sensor body, the device may be effectively used as a device for detecting an analyte in a sample, since typically a change in the size, appearance, light absorption, light emission and / or fluorescence of the sensor body may occur when an analyte binds to the sensor body.

[0033] In an embodiment of the device according to the invention, the means for controlling and cycling the temperature in the container may be any suitable means, for example one or several Peltier elements, alone or coupled with a heat sink, which are thermally connected to the container. Preferably, such means for controlling and cycling the temperature in the container are computer-controlled, i.e. connected to a suitable computer operable by a user. For example, the user can program how many temperature changes to perform and what temperature values ​​to achieve / maintain, what incubation intervals, if any, to provide between the temperature changes, etc.

[0034] In an embodiment in which the device according to the invention further comprises an optical detector, it is preferred that the analyte is or will be labeled, either before, during or after binding of the analyte to the sensor body. This is particularly the case when the analyte itself is not easily detectable beforehand by optical means. In this embodiment, i.e. when the analyte is specifically labeled, the analyte can be detected using the optical detector once bound to the sensor body. In an embodiment in which the device according to the invention further comprises an optical detector, the container is at least partially transparent (with respect to the wavelength range in which detection is performed) to allow optical detection of the sensor body in the container and / or the analyte bound to the sensor body by the optical detector. In an embodiment of the invention, it is preferred that the container can be sealed or closed to provide a predefined reaction or incubation space.

[0035] Suitable labels for analytes are known to those skilled in the art and may be, for example, fluorescent dyes or visible dyes, which may be bound to said analytes directly or by other means, for example, via antibodies. Sometimes herein, such labeled antibodies are also referred to herein as labeled detection antibodies ("labeled detection ABs").

[0036] In embodiments where the device according to the invention further comprises means for mechanically agitating the aqueous sample if present in said container, it is possible to mechanically agitate the sample suspected of containing the analyte, thereby achieving efficient macroscopic liquid exchange around the sensor body or bodies. Without wishing to be bound by any theory, the inventors believe that such mechanical agitation increases and supports the flow of material through any binding surfaces (e.g. interstitial pore spaces within said sensor body, or capture agents attached to the porous polymer scaffold of said sensor body or bodies), thereby enhancing the efficiency of any binding of analyte to said sensor body or bodies. The means for mechanically agitating the aqueous sample may be any suitable means, e.g. a stirrer, a pump, means for moving the container (and thus any sample therein), etc.

[0037] We describe macroscopic prefabricated sensor bodies with predefined dimensions and detectable in both their expanded and their contracted states. The bodies can be observed as individual structures to detect bound analytes during the incubation / concentration process before binding is performed. Furthermore, individual sensor body elements can be subjected to multiple phases of shrinkage / swelling cycles. Structural integrity is preferably achieved by cross-linking the polymer. Cross-linking is achieved either by employing specific cross-linking reagents that cross-link between polymer chains in three dimensions or by employing suitable (planar) substrates that provide connections between polymer chains via fixation to this single surface.

[0038] The sensor body is typically arranged in the form of floating particles or in the form of a sensor spot on a flat substrate. The sensor body has a predefined size and shape in each of its expanded and contracted states. The volume difference between the two states is proportional to the total pore volume accessible to the aqueous solvent in the expanded state. Useful sensor bodies are preferably characterized by a volume difference of >50% between the two states, preferably greater than 80%, ideally greater than 90%. In addition, the sensor body is characterized by a characteristic pore size distribution, where some pores allow access of the analyte / label, while other pores are too small and only solvent accessible.

[0039] In a still further embodiment the present invention relates to the use of a sensor body according to the invention for concentrating an analyte and / or for purifying and / or washing and / or detecting an analyte.

[0040] In one embodiment of said use, said analyte is, or becomes, bound to a surface during such use, preferably said surface is a surface of said sensor body.

[0041] In one embodiment, the analyte is labeled with a detectable label.

[0042] In one embodiment, the analyte is contained in a sample, the sample being an aqueous solution or a bodily fluid, preferably selected from blood, plasma, serum, saliva, urine, tears, sweat, lymphatic fluid, semen, and cerebrospinal fluid.

[0043] According to an embodiment of the present invention, the inventors have come up with an embodiment of a sensor body for binding and / or concentrating an analyte, the sensor body comprising a porous polymer scaffold and an interstitial pore space within said polymer scaffold. The sensor body can be used in a number of applications, such as binding assays, purification protocols, detection methods, amplification methods and similar methods. The porous polymer scaffold of said sensor body is preferably composed of a thermoresponsive polymer, and one or more capture agents are attached to said porous polymer matrix. The use of a thermoresponsive polymer allows the sensor body to assume two different states, namely, one state in which the sensor body is expanded, and also swollen when subjected to an aqueous solvent. In the other state, the sensor body contracts and most of the solvent previously occupying the interstitial pore space is pushed out. The sensor body according to the present invention can be cycled between the two states, thus allowing the reversible uptake and expulsion of water from the interstitial pore space, thus allowing washing of the sensor body and any analytes attached thereto without the need to use new liquid / buffer.

[0044] The term "sensor body" as used herein is meant to refer to a physical entity comprising a porous polymer scaffold and interstitial pore spaces within said polymer scaffold. The sensor body may be, according to an embodiment of the present invention, a particle not attached to any surface or a spot immobilized on the surface of a substrate. In either case, the outer physical boundaries of said sensor body, i.e. said particle and said spot, are optically recognizable and in both situations can be visually observed or detected, preferably with a microscope or other optical means. When the sensor body is configured to be in the form of a particle, it is typically an isolated particle that is not attached to the surface of a substrate or to another particle or entity. In a preferred embodiment, the sensor body is freely diffusible and, for example, buoyant when in an aqueous environment. When the sensor body is configured to be in the form of a spot, it is typically immobilized on the surface of a substrate, preferably the surface of a substantially flat substrate. In this case, the sensor body, i.e. the spot, is immobilized and therefore not freely diffusible and not buoyant when in an aqueous environment. When the sensor body is configured in the form of a spot, it may also be configured to be an array of spots immobilized on a surface. The immobilization of such spots on the surface may be performed by any suitable means, typically involving crosslinking the polymers constituting said spots on or with the surface. The immobilization of the spots on the surface of such a substrate may be direct, without any intervening layer, or may involve the use of a suitable layer, for example an attachment layer, which facilitates the immobilization of said spots on the surface. The sensor body may also be configured to provide a more or less defined surface-spread coating on the substrate. In embodiments involving a substrate, the invention also envisages an assembly of said spots and said substrate, or of said coating and said substrate, which assemblies form part of the invention.

[0045] The sensor body, either in its particulate form, in its spot form or as a coating, can assume two different states depending on the external conditions to which it is exposed. Taking temperature as an example of an external condition and assuming an embodiment in which the sensor body comprises a porous polymer scaffold composed of a thermoresponsive polymer, the sensor body can be in an expanded state under one set of temperature conditions and in a contracted state under another set of conditions. When the sensor body is in an aqueous environment and in an expanded state, it is also in a swollen state, meaning that the pore space of its interstitial spaces is filled to a significant extent or to a large extent with water. When the conditions change, for example in the case of an LCST polymer, when heated above the lower critical solution temperature (LCST), the polymer begins to contract and the sensor body assumes a contracted state, and any water present in the pore space of the interstitial spaces begins to be expelled therefrom. When the temperature falls again below the LCST, the polymer relaxes again and the sensor body returns to an expanded state again, thereby allowing the uptake of water into the pore space of the interstitial spaces. The sensor bodies according to the invention can be reversibly cycled between these two states. Furthermore, the sensor bodies according to the invention are also easy to handle, since they are of predefined dimensions, as opposed to undefined aggregates that simply precipitate out of solution when external conditions change. This is because the sensor bodies according to the invention are prefabricated, which means that their manufacture can be performed separately from their subsequent use in a detection reaction. Furthermore, the sensor bodies according to the invention can be stored for long periods of time, and the sensor bodies according to the invention can also be dried, for example lyophilized. Furthermore, the sensor bodies according to the invention can be easily detected and recognized from their respective surroundings.

[0046] Without wishing to be bound by any theory, the inventors believe that the presence of interstitial pore spaces in the sensor body, i.e. in the particles or spots, according to the present invention is achieved by preferably crosslinking the polymers constituting said sensor body. Such crosslinking may be introduced during the polymerization process, for example by using bi- or polyfunctional monomers, or by using a separate crosslinking agent altogether, or such crosslinking may be achieved after polymerization by subsequent chemical reactions. It is noteworthy that the crosslinking agent according to the present invention is not an antibody or an antibody fragment. A typical example of a suitable crosslinking agent, for example a crosslinking agent for pNIPAM, is N,N'-methylenebisacrylamide. Crosslinking may be performed in the bulk of the polymer, especially for sensor bodies designed as particles. Such crosslinking is sometimes also referred to herein as bulk crosslinking. If the sensor body is configured to be a spot or an array of spots or a surface coating of a predefined size, crosslinking may be achieved by interfacial crosslinking, meaning that the polymer of said spot or said coating is crosslinked to the surface of the substrate. However, in addition to such interfacial crosslinking, spots or coatings according to the present invention may still also include some degree of bulk crosslinking as outlined and defined above.

[0047] According to an embodiment of the invention, the porous polymer scaffold is composed of a polymer that is responsive to an external trigger, which may be a physical trigger, such as temperature or pressure, or a chemical trigger, such as the presence or absence of a particular chemical or pH value to which the sensor body is exposed. In a preferred embodiment, such an external trigger is temperature and the responsive polymer is a thermoresponsive polymer, such as a lower critical solution temperature (LCST) polymer or an upper critical solution temperature (UCST) polymer.

[0048] The term "pores" as used herein refers to channels, cavities, tunnels, lumens or holes in the sensor body into which chemical moieties can diffuse depending on their size and the size of such pores. The totality of such pores constitutes the "interstitial pore space" in the sensor body. The interstitial pore space of the sensor body is contained within the porous polymer scaffold of the sensor body. The porous polymer scaffold of the sensor body is preferably composed of a thermoresponsive polymer. The term "thermoresponsive polymer" refers to a polymer whose physical properties, in particular its affinity for water, depend on the external temperature to which the polymer is exposed. In one embodiment, the thermoresponsive polymer according to the invention shows a change in affinity for water depending on temperature. In a preferred embodiment according to the invention, the thermoresponsive polymer is a thermoresponsive polymer having a lower critical solution temperature (LCST), meaning that below such lower critical solution temperature the polymer is in a hydrated expanded state and above the lower critical solution temperature the polymer is in a contracted unhydrated state. By cycling the sensor body between the two states, it is possible to repeatedly and reversibly accept water / solvent into the sensor body and then expel it again from the sensor body. This achieves a washing action. Such a washing action is achieved in particular when the interstitial pore space has a pore size distribution such that a predefined proportion of the total liquid volume accepted in the particle, for example 10% to 90% of the total liquid volume, is inaccessible to the analyte and / or label (e.g. due to the size of the analyte). When the sensor body is in the expanded state, the solvent has access to all or substantially all the pores or a predefined proportion of the pores, and the analyte has access to only a portion of the (larger) pores. When the sensor body is transformed to the contracted state, the solvent is squeezed out of the interstitial pore space, leaving only the bound analyte in / within the sensor body, whereas the other (unbound) solutes are washed away, since they are not retained by any capture agent in the "squeezed" pores. In one embodiment, the particulate sensor bodies according to the invention have an average size in the range of 1 μm to 1 mm.The term "having an average size ranging from," when used in conjunction with a sensor body according to the present invention, is meant to refer to the longest dimension of such sensor body. In one embodiment, such longest dimension of such sensor body is the diameter of such sensor body, particularly where the sensor body itself has a spherical, semi-spherical, globular, hemispherical or similar "speckle-like" or "droplet-like" shape.

[0049] In one embodiment, in the expanded state of the sensor body, the pores have a size such that the analyte does not have access to more than 90% of them, but water does. This is particularly useful for enrichment and concentration of the analyte on the surface of the sensor body, and allows efficient washing when the sensor body is reversibly cycled between the expanded and contracted states. In another embodiment, in the expanded state of the sensor body according to the invention, both the analyte and the solvent have access to most of the pores, for example 90% or more. This effectively results in a very large surface available for binding of the analyte, and at the same time, efficient washing can also be achieved when the sensor body is reversibly cycled between the two states.

[0050] In one embodiment, the volume of the sensor body, preferably the volume of the pore space of the interstitial space, defines and limits the dimensions of the space or compartment available for binding, concentrating, washing or detection of analytes, i.e. the dimensions of the space or compartment available for any application in which the sensor body is used.

[0051] In one embodiment, a particulate sensor body or sensor spot according to the invention comprises a volume in the range of 0.5 fL (1 μm diameter) to 0.5 μL (1 mm diameter).

[0052] Particulate sensor matrices according to the invention can be easily produced as aqueous droplets in a non-aqueous phase, for example by emulsion polymerization of a thermoresponsive polymer, using for example a commercially available droplet generator. Their production may be carried out separately from the subsequent detection reaction, both in time and space. The polymer droplets thus produced can then be transferred from the non-aqueous phase to the aqueous phase. The capture agents may be attached to the individual monomers before polymerization, or the capture agents may be attached to the thermoresponsive polymer after polymerization. The sensor spots can be produced using state-of-the-art micropipetting or microarraying techniques by spotting the reagents on a suitable substrate.

[0053] In embodiments including a substrate, the substrate may be any substrate suitable for immobilizing spots according to the present invention, such as a glass slide, a chip, and the like.

[0054] In one embodiment, a sensor body according to the present invention comprises a porous polymer matrix and an interstitial pore space within said polymer matrix, said porous polymer matrix being composed of a thermally responsive polymer, and one or more capture agents being attached to said porous polymer matrix.

[0055] The term "Strep-tag®" as used herein typically refers to a peptide having the sequence -Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly-COOH (Strep-tag®) or ···-Asn-Trp-Ser-His-Pro-Gln-Phe-Glu-Lys-··· (Strep-tag® II) that binds to streptavidin (Strep-Tag® and Strep-tag® II) or an engineered form of streptavidin, i.e. "StrepTactin®" (Strep-tag® II), but in a high affinity and reversible manner.

[0056] The term "logD" as used herein is meant to refer to the logarithm of the partition coefficient (D), which is the ratio of the concentrations of a compound in a mixture of two immiscible phases at equilibrium. In a preferred embodiment, the term "partition coefficient" as used herein is used synonymously with "partition coefficient". In a preferred embodiment, "partition coefficient" refers to the ratio of the concentrations of a compound in a mixture of water and 1-octanol. Typically, such measurements of partition coefficients are performed by any suitable technique known to those skilled in the art. Such suitable techniques include the "shake flask technique" in which the compound in question is dissolved in a given volume of octanol and water, and then the concentration of such compound in each solvent is further measured. Other suitable techniques include high performance liquid chromatography (HPLC). In such HPLC techniques, the partition coefficient (D) and its logarithm can be determined by correlating its retention time with similar compounds with known partition coefficient values.

[0057] According to an embodiment of the invention, a capture agent is attached to the porous polymer scaffold at the surface of the sensor body. In another embodiment, a capture agent is attached to the porous polymer scaffold in the pore space of the gap. In yet another embodiment, a capture agent is attached to the porous polymer scaffold both at the surface of the sensor body and in the pore space of the gap. Both arrangements, i.e. on the surface of the sensor body and in the pore space of the gap, can be freely adjusted depending on the intended use of the sensor body according to the invention.

[0058] The inventors have surprisingly found that the above-mentioned state-of-the-art limitations can be overcome by employing a sensor matrix according to the invention as defined herein, and by using a new assay scheme. An embodiment of this scheme employs a new kind of sensor body that includes or consists of a crosslinked polymer that is responsive to changes in external conditions, such as a temperature-responsive polymer (e.g., pNIPAM or similar polymer). Without wishing to be bound by any theory, the inventors believe that a temperature-responsive polymer (or thermo-responsive polymer), such as an LCST polymer, undergoes a reversible lower critical solution temperature (LCST) phase transition from a swollen, expanded state to a contracted state when heated in an aqueous environment above a predefined temperature (e.g., 32° C. for pNIPAM). Without wishing to be bound by any theory, during this transition, the pre-swollen polymer scaffold of the sensor body becomes hydrophobic and substantially loses volume (up to more than 90%). Most of the aqueous liquid contained within the pores of the microsensor body is expelled. The polymer may be modified to accept a capture agent (e.g., an antibody) on an accessible surface of the microsensor body. When such a surface-coated sensor body is contacted with a solution containing an analyte, the analyte is expected to bind to the capture agent (or "binding element") and thus be immobilized on the sensor body surface. If a labeling agent with affinity for the analyte is also present in the solution or added to the solution, it is expected to bind to the bound analyte on the sensor body. When the temperature is brought above a particular LCST, the sensor body undergoes a phase transition, which causes liquid to be forced out from within the sensor body.

[0059] In embodiments, this process can be repeated, thus achieving an efficient exchange of material. By repeating temperature cycling between temperature levels above and below the LCST, a periodic exchange of liquid is achieved on the surface of the sensor body. This allows for efficient enrichment of analytes and labels from the solution on the surface of the sensor body.

[0060] For detection, the sensor body is simply heated above the LCST once the enrichment process is complete or after any time appropriate for the binding reaction. The signal detected in association with the sensor body is expected to come only from the bound analyte and is not expected to be compromised by any unbound material when all the liquid has been expelled from the microsensor body. By applying this very basic approach, a wide variety of assays can be constructed that do not require any washing steps and allow the use of simple direct labeling rather than the sophisticated tools normally required for homogeneous assays. In another embodiment, the responsive polymer is a UCST thermoresponsive polymer where the same considerations as above apply but in the opposite direction.

[0061] In the following, the basic components involved in such binding assays are exemplarily exemplified hereinafter, for example based on a fluorescent sandwich immunoassay.

[0062] The present invention addresses many of the problems in performing analyte binding assays through the following exemplary aspects.

[0063] I. Signal Intensity It is desirable to increase the volume of the sensor body in order for the analyte to bind to the detectable label that serves as the signal generating means. However, when optical means are used for detection, it is very useful to concentrate the volume of the signal generating means as small as possible in order to generate the maximum possible signal intensity per unit of volume in which the signal is collected. The outlined sensor body, in which a capture agent is immobilized on its surface, in particular on the exposed surface of the porous polymer matrix and thus on the surface of the interstitial pore space, allows to efficiently increase the signal generated by the bound material.

[0064] The signal attached to the sensor body is proportional to the number of labels bound to the sensor body divided by the total volume of the sensor element. The smaller the sensor body, the higher the signal. This is shown in FIG. 3.

[0065] The images in Figures 4a and 4b show microparticles consisting of biotinylated pNIPAM with phycoerythrin-streptavidin (PE-SA) conjugates attached below (Figure 4a) and above (Figure 4b) the LCST. Because the PE-SA conjugates, with molecular weights of over 300 kDa, are larger than the average pore size of the sensor body according to this embodiment, binding occurs predominantly at the outer surface of the sensor body. Hence, the signal is concentrated at the outer edge of the sensor body.

[0066] II. In situ (homogeneous) cleaning with clean buffers, efficient unmasking of surfaces, size exclusion One particular advantage of this approach is provided by the fact that the size distribution of the sensor body pores is tunable, such that a given fraction of the pores will not absorb any macromolecules, whereas other pores are of a size suitable for uptake of larger molecules. Thus, the sensor body essentially absorbs liquid purified from macromolecules. Contraction of the sensor body expels the liquid from within the sensor body, serving as a clean buffer for washing the surfaces of the larger pores. The size-selective uptake can be seen from FIG. 5.

[0067] Figure 5 shows a swollen microparticle against a fluorescent background from phycoerythrin-streptavidin (PE-SA) in phosphate buffered saline (PBS). The sensor body of the particle has small pores and does not allow proteins to enter the interior. However, the buffer is absorbed, resulting in a localized increase in PE-SA in close proximity to the sensor body (Figure 5a). When the temperature is increased above the LCST, the buffer is expelled and thus clean buffer surrounds the sensor body. This is reflected in Figure 5b by the dark halo around the shrunken microparticle.

[0068] This particular property of the sensor body embodiment allows for exposing the sensor body surface to clean liquid without externally exchanging the liquid, an approach that, to the inventors' knowledge, has not been described before.

[0069] The size exclusion feature provides increased robustness against masking effects by larger molecular aggregates or cells present in the sample. The porous structure and interstitial pore space ensures the exclusion of materials larger than the analyte. Furthermore, the liquid expelled from the interior after each temperature cycle ensures efficient removal of any material attached to the surface of the sensor body, making the sensor body particularly useful for sample-based assays that contain large structures or debris that may cover any binding regions or capture agents and make them otherwise inaccessible to the analyte.

[0070] III. Enrichment by Periodic Expansion / Contraction The expansion / contraction cycle provides an opportunity to increase the exchange rate of material / liquid at the sensor body surface. This allows for active pumping of liquid through the sensor body, thus reducing the incubation time required for all interactions between the sample liquid and the sensor body surface. Thus, compared to conventional sensor matrices used in binding assays, the proposed sensor body and assay method allows for reduced incubation times and increased binding efficiency.

[0071] Traditionally, the capacity of a sensor body, reflected by its surface area / volume and incubation time, defines its ability to capture analytes from a sample, and therefore the capture efficiency and assay sensitivity. When particles are used, the rule is that the more particles provided, the higher the chance of binding and the less time required to achieve binding. However, increasing the number of particles used in an assay reduces the signal per particle. Therefore, incubation time and number of particles must be carefully balanced for each assay and are therefore important parameters for optimization. An increase in capture efficiency does not necessarily result in improved sensitivity if the signal per sensor body is reduced. The new temperature cycling process facilitates improved liquid exchange and therefore increases the binding per particle per unit time. This results in a reduction in incubation time and fewer particles are used in the assay. Figure 6 illustrates the effect of increasing the number of particles on the signal intensity and illustrates the value of efficient liquid exchange. Data calculated per particle using average volumes of 1 nL and 10 nL is based on the assumption that 30% of the new liquid is exposed to the sensor body surface in each particle per cycle. The total volume of the sample is set to 100 μL.

[0072] The proposed approach and novel particles allow for the use of fewer sensor bodies without compromising capture efficiency, and it also allows for improved sensitivity by simply performing more temperature cycles. In certain embodiments, for example, the following items are provided: (Item 1) A sensor body for binding and / or concentrating an analyte, the sensor body comprising a porous polymer scaffold and interstitial pore space within the polymer scaffold, the porous polymer scaffold being composed of a polymer that responds to changes in at least one external condition to which the sensor body is exposed, such as changes in pH, temperature, salt conditions, the presence or absence of a chemical, and having one or more capture agents for the analyte attached to the porous polymer scaffold. (Item 2) The polymer responsive to a change in the at least one external condition to which the sensor body is exposed is a thermoresponsive polymer, the thermoresponsive polymer being a thermoresponsive polymer having a lower critical solution temperature (LCST polymer), preferably selected from poly(N-isopropylacrylamide) (pNIPAM), poly[2-(dimethylamino)ethyl methacrylate] (pDMAEMA), hydroxypropyl cellulose, poly(vinyl caprolactam) (P(VCL), and polyvinyl methyl ether); or the thermoresponsive polymer is a thermoresponsive polymer having a lower critical solution temperature (LCST polymer). 2. The sensor body according to item 1, wherein the thermoresponsive polymer is a thermoresponsive polymer having an upper critical solution temperature (UCST), preferably any one selected from poly(N-acryloylglycinamide) (PNAGA), poly(allylamine)-co-poly(allylurea) and its derivatives, poly(methacrylamide), poly(N-acryloylaspartamide), poly(N-methacryloylglutamine amide), poly(acrylamide)-co-(acrylonitrile), poly(sulfobetaine), poly(phosphorylcholine). (Item 3) The sensor body according to any one of the preceding items, wherein the responsive polymer, in particular the thermoresponsive polymer, is crosslinked, preferably by at least one crosslinking reagent which bridges between and interconnects different polymer chains within the polymer, or by providing a substrate, in particular a substantially flat substrate, adjacent to the sensor body and interfacially crosslinking different polymer chains of the polymer to the substrate, in particular to the surface of the substrate, more preferably wherein the at least one crosslinking reagent is not an antibody or an antibody fragment. (Item 4) 2. The sensor body of claim 1, wherein the sensor body has the ability to reversibly assume expanded and contracted states, and preferably, when the sensor body is in the expanded state, the interstitial pore space has a volume of at least 50%, preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90% of the total volume of the sensor body. (Item 5) A sensor body according to any one of the preceding items, wherein approximately 10% to 90% of the total volume of the pore space of the gap is not accessible to the analyte but is accessible to a solvent, preferably water. (Item 6) The sensor body according to any one of the preceding items, wherein the analyte is a biomolecule selected from nucleic acids, preferably DNA or RNA, nucleotides, oligonucleotides, proteins and peptides, lipids, e.g. phospholipids, preferably the biomolecule has a size of >0.1 kDa, e.g. 0.5 kDa, preferably >5 kDa, more preferably >10 kDa, even more preferably >50 kDa, or the analyte is a virus or a cell. (Item 7) 2. The sensor body of any one of the preceding claims, wherein the pore space of the interstitial space is dimensioned to receive liquid from a liquid sample containing or suspected of containing the analyte. (Item 8) The capture agent is specific for a given analyte and is selected from antibodies, antibody fragments, aptamers, nucleic acids including spiegelmers, non-antibody proteins capable of specifically binding to the analyte or analyte complex, such as receptors, receptor fragments, affinity proteins, chemical moieties such as streptavidin, biotin, Strep-tag®, digoxigenin, dinitrophenol, nucleic acid tags or nucleic acid analogue tags, or similar chemical moieties capable of specifically binding, or D =10 -8 From 10 -15The sensor body according to any one of the preceding items, wherein the sensor body is selected from a hydrophobic structure capable of specifically binding to an antibody, an antibody fragment, an aptamer, a nucleic acid including a spiegelmer, a non-antibody protein, such as a receptor, a receptor fragment, an affinity protein, such as streptavidin, with an affinity in the range of M, or capable of specifically binding to a hydrophobic molecule or a molecule having a hydrophobic group, preferably the hydrophobic structure has a logD of greater than 2 under conditions under which the detection of the analyte is performed. (Item 9) 2. A sensor body according to any one of the preceding items, which is either a freely diffusible isolated particle or a spot immobilized on the surface of a substrate. (Item 10) 10. The sensor body according to item 9, which is preferably a freely diffusible isolated particle, said isolated particle having a spherical or spherical shape, preferably having a spherical or spherical shape and having clearly defined boundaries which can be observed visually, preferably by microscope or other optical means. (Item 11) 11. The sensor body according to item 9 or 10, having an average diameter in the range of 1 μm to 1 mm. (Item 12) A spot immobilized on the surface of a substrate, said spot having clearly defined boundaries that can be observed visually, preferably by a microscope or other optical means, and preferably having a size of less than 1 μm 2 From 1mm 2 10. The sensor body of claim 9, wherein the particles cover an average fixed area on the substrate in the range of 0.1 to 0.5 nm, and the thickness of the particles varies depending on the external condition to which the spots are exposed and therefore depending on whether the spots are in an expanded or contracted state. (Item 13) 1. A method for binding an analyte to a sensor body, comprising the steps of: a) providing, in any order, a sensor body according to any one of items 1 to 12 and an aqueous sample suspected of containing the analyte; b) exposing the sensor body to the aqueous sample, thereby allowing analytes present in the sample to bind to the sensor body and allowing liquid into the interstitial pore space of the sensor body. A method comprising: (Item 14) 1. A method for concentrating and / or washing an analyte bound to a sensor body, comprising the steps of: c) carrying out the method according to item 13; d) changing the state of the sensor body from an expanded state to a contracted state by changing at least one external condition to which the sensor body is exposed, such as one of temperature, pH, salt concentration, presence or absence of a chemical, thereby forcing out the liquid contained in the interstitial pore space of the sensor body; e) changing the state of the sensor body from a contracted state to an expanded state by changing at least one external condition to which the particles are exposed, such as one of temperature, pH, salt concentration, presence or absence of a chemical, thereby admitting liquid into the interstitial pore space of the sensor body. Including, If the analyte is bound to the particle, steps d) and e) are performed after step c), and the analyte is either labeled or unlabeled; wherein steps d) and e) are repeated n times, n being an integer in the range of 1 to 1000, preferably 1 to 500, preferably 1 to 250, more preferably 1 to 100, even more preferably 1 to 50, more preferably 1 to 40, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, even more preferably 1 to 20, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20. (Item 15) 15. The method according to claim 14, wherein during the performance of steps c) to e), the sensor body is surrounded by a bulk aqueous solution, e.g. the aqueous sample, and during at least one of steps c) to e), the liquid around the sensor body is exchanged by stirring the bulk aqueous solution. (Item 16) 1. A method for detecting an analyte in a sample, comprising: - carrying out the method according to any one of items 13 to 15, wherein the analyte is or will be labelled either before, during or after binding of the analyte to the sensor body; - detecting said analyte bound to said sensor body by detecting said label bound to said sensor body, preferably in the presence of unbound label. A method comprising: (Item 17) 17. The method according to any one of items 13 to 15 and 16, carried out in a single reaction vessel. (Item 18) 1. A device for binding and / or concentrating an analyte, comprising: - a container for receiving a plurality of sensor bodies as defined in any one of items 1 to 12 and for receiving an aqueous sample suspected of containing the analyte; - a plurality of sensor bodies as defined in any one of items 1 to 12 contained in said container, wherein the polymer scaffold of said sensor bodies is composed of a thermoresponsive polymer; - means for controlling and cycling the temperature in said container; and - optionally, means for mechanically agitating the aqueous sample if present in said container; Including, the device. (Item 19) - a sensor body within said container, and an optical detector configured to detect changes in size, appearance, light absorption, light emission and / or fluorescence of said sensor body. Item 19. The device of item 18, further comprising:

[0073] Further reference will be made to the drawings. [Brief description of the drawings]

[0074] [Figure 1] 1 shows an embodiment of a particulate sensor body according to the invention showing a particle comprising a porous polymer scaffold with interstitial pore space within said polymer scaffold, said porous polymer scaffold being composed of a thermoresponsive polymer, one or more capture agents in the form of capture antibodies attached to said porous polymer scaffold, also showing a detectable label in the form of a fluorophore label attached to a further antibody, analyte, other antigens and solvent in the sample.

[0075] [Diagram 2] 2 shows the reversible process of conversion of the sensor body between an expanded, swollen state and a contracted state. Such conversion can occur by changing at least one external condition to which the sensor body is exposed, such as temperature, pH or salt concentration. In a preferred embodiment, such conversion occurs by changing the temperature to which the sensor body is exposed.

[0076] [Diagram 3] 3 shows the dependence of the signal associated with a particulate sensor body (=particle) comprising an LCST polymer on the volume of the particle (for example because a labeled analyte is bound to said sensor body). At temperatures above the LCST, the sensor body has a smaller diameter and the signal intensity is greater. At temperatures below the LCST, the sensor body has a larger diameter and the signal intensity is smaller.

[0077] [Figure 4]Figure 4 shows images of biotinylated pNIPAM particles with phycoerythrin-streptavidin (PE-SA) conjugates attached below the LCST (Figure 4a) and above the LCST (Figure 4b), where the PE-SA conjugates have a molecular weight of over 300 kDa, which is larger than the average pore size of the sensor particles in this embodiment, so binding occurs predominantly at the outer surface of the particles in this embodiment. Hence, in this example, the detectable signal is concentrated at the outer edge of the particles.

[0078] [Diagram 5] Figure 5 shows an embodiment of a swollen particle against a fluorescent background from PE-SA in phosphate buffered saline (PBS). In this embodiment, the particle has small pores that do not allow proteins to enter the interior. However, the buffer is absorbed, which causes a localized increase in PE-SA in close proximity to the particle (Figure 5a). When the temperature is increased above the LCST, the buffer is expelled, and thus clean buffer surrounds the particle. This is reflected by a dark halo around the particle (Figure 5b).

[0079] [Figure 6] Figure 6 shows the effect of increasing particle number on signal intensity (left y-axis). In addition, the graph illustrates the values ​​of liquid exchange (right y-axis). Data are calculated per particle using average volumes of 1 nL and 10 nL, based on the assumption that 30% of the new liquid is exposed to the particle surface every cycle. The total volume of the sample is set to be 100 μL.

[0080] [Figure 7] Figure 7 shows a graphical representation of an embodiment of a sensor spot consisting of a sensor body with different binders ("capture agents") (1, 2, 3) attached to it. The spots are attached to the surface of a substrate. A chemical attachment layer is shown, which provides better attachment, especially when no other crosslinking agents are used to crosslink the individual polymer molecules.

[0081] The graph illustrates the swelling / shrinking effect. On the right side, microscopic images of such sensor spots in swelling (top) and shrinking (state) are shown. The white color is due to light diffraction by the densely packed shrunken matrix, whereas the swollen matrix appears almost transparent. In a slightly different embodiment, the various spots may be interconnected or connected to each other, thus forming a coating of defined dimensions on the surface of the substrate.

[0082] [Figure 8] FIG. 8 illustrates the principle of an assay according to an embodiment of the invention, where an antigen, e.g., dengue NS1 antigen, is bound, enriched, and detected using a sensor body according to the invention, e.g., a pNIPAM sensor body, in an immunoassay format comprising a capture agent, e.g., a capture antibody (capture AB) and a labeled detection antibody (detection AB). In this example, the sensor body (sometimes also referred to as "particle" in this specification and drawings) is labeled with biotin ("Bio") ("biotin-labeled capture particle"), and the capture antibody is coupled to streptavidin ("streptavidin-coupled capture AB") and attached to the sensor body via the biotin-streptavidin bond. The sensor body is exposed to a sample spiked with an analyte, e.g., dengue NS1 antigen, and subjected to cyclic changes in temperature (20-50 times, e.g., 40 times) (using suitable temperature control means, e.g., a Peltier element controlled by a computer), causing the sensor body to reversibly adopt expanded and contracted states. If necessary, the sample may also be mechanically agitated by any suitable means, such as a pump, a stirrer, shaking of the entire reaction vessel / container, and the like.

[0083] The binding of the analytes by the sensor body and their enrichment as well as the detection are carried out in the same vessel, e.g. in the container of the device according to the invention. The enrichment is carried out to such an extent that no washing steps or transfer to another vessel is necessary. Thus, according to the invention, the method according to the invention is sometimes referred to herein as a "one-pot method" or "one-pot protocol" since it can be carried out in a single vessel.

[0084] [Figure 9] FIG. 9 shows the characterization of the binding capacity and signal intensity of six exemplary different sensor bodies ("pNIPAM particle formulations") according to an embodiment of the present invention using pNIPAM as the polymer constituting the porous polymer scaffold (labeled "1" to "6" beneath the bar graph). The top part of the figure shows plots of the (fluorescence) signal intensity of each sensor body 1 to 6 after binding and enrichment of the analyte (NS1 in this case) to the sensor body. For each sensor body 1 to 6, the signal is shown as a pair of two bars next to each other, i.e., when the sensor body is in a contracted state (light grey bar on the right side of each pair), i.e., above the LCST of the polymer, and when the sensor body is in an expanded state (dark grey bar on the left side of each pair), i.e., below the LCST of the polymer. It is clear that the signal is significantly stronger when the sensor body is in the contracted state. Various particles / sensor bodies were synthesized (indicated by numbers 1 to 6 beneath the respective bars in the graph). The particles differed with respect to the concentration of polymer, the type and concentration of comonomer, and the degree of crosslinking. More specifically, the composition of the particle / sensor body was as follows: [Table 1]

[0085] The lower part of the figure shows images of the fluorescent sensor body at optimal exposure settings, with the sensor body shown in an expanded state (top row) and a contracted state (bottom row). The top graphs are normalized to an exposure time of 1 second.

[0086] [Figure 10] Figure 10 shows the results of a detection assay following the principle outlined in Figure 8. A diluted sample of spiked NS1 serotype 2 from ICL (http: / / www.icllab.com / ) was incubated with NS1 capture antibody ("01961-streptavidin", antibody obtained from http: / / www.meridianbioscience.eu / , streptavidin labeling kit obtained from https: / / www.expedeon.com / products / protein-antibody-conjugation / lightning-link-antibody-labeling-kits / biotin-streptavidin-labeling-kits / ; labeled according to the manufacturer's instructions). The assay was carried out using a (biotinylated) sensor body according to the invention with an attached (biotinylated) antibody (recognition antibody) and further using a labeled detection antibody ("1838-R-phycoerythrin", antibody obtained from http: / / www.meridianbioscience.eu / , R-phycoerythrin labeling kit from https: / / www.expedeon.com / products / protein-antibody-conjugation / lightning-link-antibody-labeling-kits / fluorescent-dyes-and-proteins / ; labeling according to manufacturer's instructions). The sensor body was exposed to a diluted sample with a defined concentration of NS1 and temperature cycling was carried out 20-50 times as described for FIG. 8. The assay showed very good performance even without elaborate optimization. Even lower concentrations of antigen (2 ng / ml, 5 ng / ml) could be reliably and clearly distinguished from the negative control sample. The left panel is a partial enlargement of the right panel of the figure. Also shown is a negative control (plasma without antigen), in which the sensor body is largely recognizable, but no significant fluorescent signal is detectable. EXAMPLES

[0087] The following examples are further provided for illustrative purposes and do not limit the invention.

[0088] Example 1 Synthesis of detection particles 2. Preparation of Sensorbody Polymerization Mix Component 1 (aqueous phase): Components per mL of Polymerization Mix [Table 2] Component 2 (Oily Phase): [Table 3]

[0089] The mixes were degassed separately with four degass-purge cycles and purged with argon. The mixes were then pipetted under argon into the respective wells of a BioRad Droplet Generator Chip DG8. 60 μl of oil phase was placed in each oil phase reservoir and 25 μl of aqueous phase was placed in each aqueous phase reservoir.

[0090] BioRad's protocol for droplet generation was then followed (QX200™ Droplet Generator Instructions Manual 10031907 RevC). Alternatively, the chip could also be operated manually. For that purpose, a 50 mL syringe needs to be connected to the droplet reservoir of the droplet generator chip by means of a tube and a suitable adapter. Before connecting, the plunger is set to the 30 mL position. After filling the aqueous and oil phases, the plunger is manually extended to the 50 mL position to apply a predefined pressure to the system. Just before the oil or aqueous phase reservoir is empty, the pressure is released.

[0091] The droplet reservoir was covered with adhesive tape. The droplets were allowed to polymerize for 60 min at room temperature. Use of Mix 1 delivers particles consisting of approximately 10% pNIPAM gel cross-linked. Mix 2 delivers particles consisting of approximately 5% pNIPAM gel cross-linked. The latter shows a larger pore width compared to the former. The percentage of gel and cross-linking can be varied.

[0092] If particles with larger sizes are required, an aliquot of the polymerization mix may be pipetted or dispensed by a suitable dispenser tool into the oil phase. A wide variety of manual or automatic dispenser tools are commercially available. Depending on the tool used, the particle size can be varied over a wide range. Multiple droplets of the polymerization mix may be dispensed into a volume of oil, as well as a single droplet per volume of oil. The combination of an automatic dispenser tool with an automatic x / y stage and a multi-well oil reservoir, such as a microtiter plate, allows the creation of a large number of particles in a short period of time.

[0093] Particle recovery and transfer to the aqueous phase After completing the polymerization process, gently withdraw as much of the oil phase as possible from the droplet reservoir using a pipette, taking care not to remove the pNIPAM particles. Then, pipette 50 μl of 1% (v / v) Triton X-100 in water onto the particles. Mix the contents by pipetting up and down to prevent the particles from sticking to the walls of the droplet tip. Transfer the contents to an Eppendorf tube and repeat this process one more time. The transfer process can be monitored under a binocular microscope to ensure that most of the particles are not lost in this step.

[0094] The tube is then centrifuged at 2000g for 1 minute. The oil phase (bottom) and the aqueous phase (top) are now well separated, with the particles contained between them. 200 μl of density gradient medium (Optiprep, Axis shield) are now slowly pipetted into the tube. It is important to avoid excessive mixing of the aqueous phase with the density gradient medium. Ideally, most of the density gradient medium will be under the particle phase. The tube is centrifuged at 2000g for 2 minutes. The density gradient medium phase is then located between the oil phase and the particle phase. The particle phase may now be transferred to a new tube. At this step, care must be taken not to transfer any oil volume to the new tube, and to keep the density gradient medium volume as small as possible.

[0095] 1 mL of PBS, 0.1% (v / v) Triton X-100 is added to the tube containing the particles. The contents are mixed and centrifuged at 2000 g for 2 minutes. The particles are now pelleted at the bottom of the tube. The supernatant is removed, leaving the particles in the tube. 1 mL of PBS, 0.1% (v / v) Triton X-100 is added again to the tube, and the washing process is repeated 5 times. Finally, the particles are dissolved in a volume of buffer suitable for the following process. This may be, for example, 100 μl of PBS, 0.1% (v / v) Triton X-100.

[0096] Observation of the behavior of the lower critical solution temperature of the sensor body 25 μl of the diluted suspension of particles is transferred to a Leja 100 μm chamber slide ( / https: / / leja.nl). The slide is placed on a Peltier element 30×30×4.7 mm, 19.3 W (Quick-Ohm, Kupper&Co. GmbH, #QC-71-1.4-3.7M) capable of rapid temperature cycling in direct contact with the heating / cooling element. The whole setup is placed under a binocular microscope equipped with dark field illumination. When the temperature of the system is set below 32°C, the sensor body is transparent and almost invisible. At 32°C or higher, the sensor body becomes opaque: i.e. the particles become white and shrink. By setting the temperature below 32°C again, the particles swell and become transparent again. This process is reversible and can be repeated many times in rapid cycles. Assuming sufficient heating and cooling rates of the Peltier elements and sufficient thermal conductivity throughout the system, cycle times (heat, shrink, cool, swell) of less than 20 seconds can be achieved.

[0097] Generation of polymerization mix for biotin-modified pNIPAM particles Component 1 (aqueous phase): Preparation of biotin-modified monomer mix: Biotin-modified acrylic acid monomers were made in separate reactions: the reaction mix consisted of acrylic acid N-hydroxysuccinimide ester (an activated amino-reactive acrylic acid monomer) and biotin-dPEG7-NH2 (a biotin derivative modified with an amino-terminated PEG7 spacer arm). [Table 4]

[0098] The reaction mix was incubated for 30 minutes at 25° C. This mix was used for the pNIPAM polymerization reaction without any further purification. Components per mL of Polymerization Mix [Table 5] Component 2 (Oily Phase): [Table 6]

[0099] The mixes were degassed separately with four degass-purge cycles each and purged with argon. The mixes were then pipetted into the respective wells of a BioRad droplet generator chip DG8 under argon atmosphere. 60 μl of the oil phase was placed in each oil phase reservoir and 25 μl of the aqueous phase was placed in each aqueous phase reservoir.

[0100] BioRad's protocol for droplet generation was then followed (QX200™ Droplet Generator Instructions Manual 10031907 RevC). Alternatively, the chip could also be operated manually. For that purpose, a 50 mL syringe needs to be connected to the droplet reservoir of the droplet generator chip by means of a tube and a suitable adapter. Before connecting, the plunger is set to the 30 mL position. After filling the aqueous and oil phases, the plunger is manually extended to the 50 mL position to apply a predefined pressure to the system. Just before the oil or aqueous phase reservoir is empty, the pressure is released.

[0101] The droplet reservoir was covered with adhesive tape. The droplets were allowed to polymerize for 60 min at room temperature. The use of Mix 1 results in biotin-modified particles ("sensor bodies") consisting of approximately 10% cross-linked pNIPAM gel. Mix 2 results in biotin-modified particles ("sensor bodies") consisting of approximately 5% cross-linked pNIPAM gel. The latter shows a larger pore width compared to the former. The percentage of gel and cross-linking can be varied.

[0102] Particle recovery and transfer to the aqueous phase After completing the polymerization process, gently withdraw as much of the oil phase as possible from the droplet reservoir using a pipette, taking care not to remove the pNIPAM particles. Then, pipette 50 μl of 1% (v / v) Triton X-100 in water onto the particles. Mix the contents by pipetting up and down to prevent the particles from sticking to the walls of the droplet tip. Transfer the contents to an Eppendorf tube and repeat this process one more time. The transfer process can be monitored under a binocular microscope to ensure that most of the particles are not lost in this step.

[0103] The tube is then centrifuged at 2000g for 1 minute. The oil phase (bottom) and the aqueous phase (top) are now well separated, with the particles contained between them. 200 μl of density gradient medium (Optiprep, Axis shield) are now slowly pipetted into the tube. It is important to avoid excessive mixing of the aqueous phase with the density gradient medium. Ideally, most of the density gradient medium will be under the particle phase. The tube is centrifuged at 2000g for 2 minutes. The density gradient medium phase is then located between the oil phase and the particle phase. The particle phase may now be transferred to a new tube. At this step, care must be taken not to transfer any oil volume to the new tube, and to keep the density gradient medium volume as small as possible.

[0104] 1 mL of PBS, 0.1% (v / v) Triton X-100 is added to the tube containing the particles. The contents are mixed and centrifuged at 2000 g for 2 minutes. The particles are now pelleted at the bottom of the tube. The supernatant is removed, leaving the particles in the tube. 1 mL of PBS, 0.1% (v / v) Triton X-100 is added again to the tube, and the washing process is repeated 5 times. Finally, the particles are dissolved in a volume of buffer suitable for the following process. This may be, for example, 100 μl of PBS, 0.1% (v / v) Triton X-100.

[0105] Observation of the behavior of the lower critical solution temperature of particles. 25 μl of the diluted suspension of biotin-modified particles is transferred to a Leja 100 μm chamber slide ( / https: / / leja.nl). The slide is placed on a Peltier element 30×30×4.7 mm, 19.3 W (Quick-Ohm, Kupper&Co. GmbH, #QC-71-1.4-3.7M) capable of rapid temperature cycling in direct contact with the heating / cooling element. The whole setup is placed under a binocular microscope equipped with dark field illumination. When the temperature of the system is set below 32°C, the particles are transparent and almost invisible. At temperatures of 32°C or higher, the particles become visible: i.e. they become opaque and shrink. By setting the temperature below 32°C again, the sensor body swells and the particles become transparent again. This process is reversible and can be repeated many times in rapid cycles. Assuming sufficient heating and cooling rates of the Peltier elements and sufficient thermal conductivity of the entire system, cycle times (heating, swelling, cooling, shrinking) of less than 20 seconds can be achieved. The inventors conclude that biotin modification of the polymer does not impair the LCST behavior of the pNIPAM sensor body.

[0106] In a control experiment, particles were synthesized using a reaction mix similar to that described above, in which the 2.5% biotin-modified monomer mix was replaced with a 2.5% acrylic acid solution, and particles formed using such a mix almost completely lost their LCST characteristics.

[0107] Specific binding of streptavidin-phycoerythrin conjugates to biotin-modified pNIPAM particles To assess whether biotin-modified pNIPAM particles were capable of specifically binding streptavidin, particles made with mixes 3 and 4 were incubated with a solution of streptavidin-phycoerythrin conjugate. Particles made with mixes 1 and 2 (no biotin modification) were incubated with the same solution as a negative control. Incubation Mix: [Table 7]

[0108] The incubation mixes were combined and mixed briefly. 25 μl of each mix were transferred to a 100 μm chamber slide from Leja (https: / / leja.nl) and placed on the Peltier element as described above. The setup was placed on a fluorescence microscope (Axio-Observer, Zeiss, Germany) equipped with a 550 nm LED light source (CooLED pE-4000), a Cy3 HC Filterset (Semrock) and a 10× Zeiss objective. The Peltier temperature was set to 20°C (below the LCST of the sensor body). The appearance of the sensor bodies was observed. The biotin-modified sensor bodies (made with polymerization mixes 3 and 4) could be detected above background by a circular fluorescent signal located mainly in the outer shell of the particle. The sensor bodies without biotin modification (made with polymerization mixes 1 and 2) do not show any fluorescent signal. The particles shrink when the Peltier temperature is set to 40°C (above the LCST). The biotin-modified particles show a strongly enhanced fluorescent signal on their surface, whereas the unmodified particles remain dark.

[0109] The incubation mix in the Leja slide was subjected to 25 temperature cycles of 10 s at 20°C followed by 10 s at 40°C. After these cycles, the fluorescence signal of the biotin-modified particles was strongly enhanced compared to the signal observed before temperature cycling. Particles without biotin modification remained dark. A striking difference is observed regarding the distribution of the fluorescence signal in the biotin-modified particles of mixes 3 and 4. Particles made with mix 3 show a bright signal on the surface of the particle but only a weak signal in the volume of the particle, which can be interpreted as a preferred binding of streptavidin-phycoerythrin on the outer surface of the particle. These particles are made with a reaction mix containing 10% NIPAM monomer. Particles made with mix 4 (containing 5% NIPAM monomer) show a maximum signal in the center of the particle, which can be interpreted as a uniform binding of streptavidin-phycoerythrin throughout the volume of the particle. For both types of particles, the fluorescent signal is much higher when the particles are monitored at 40° C. (above the LCST) compared to 20° C. (below the LCST).

[0110] Particles made with Mix 1 (10% NIPAM monomer, no biotin modification) do not bind streptavidin-phycoerythrin conjugates, but produce a fluorescent pattern with the dye in solution: when the particles are cooled below the LCST (20 °C), they swell and fill with water. The particles remain dark, but a halo brighter than the incubation mix forms at the particle boundaries. This can be interpreted as an enrichment of the dye at the particle boundaries due to the narrow pore width that prevents larger chromoproteins from entering the particle volume. This effect can be used in assays to enrich and concentrate analytes (and other large molecules) in a homogeneous process.

[0111] When the temperature is raised to 40°C (above the LCST), the particles shrink. A halo is extruded as a bright fluorescent haze from the surface of the particle. This can be interpreted as a washing action of non-fluorescent solvent being expelled from the interior of the particle and washing off unbound material from the particle surface. The latter action can be used in the assay to wash off non-specifically bound material without the need to add an external wash solution.

[0112] Example 2 Establishment of a fluorescence-based immunoassay using freely diffusible / suspended particles as sensor bodies Here we describe a process to establish a fluorescence-based immunoassay for the detection of human cardiac troponin I (cTnI). The assay employs a detection antibody labeled with a fluorescent dye. The capture antibody is labeled with streptavidin and coated onto biotin-modified pNIPAM particles. A sandwich complex of the particles bound with the capture antibody, antigen and fluorescent detection antibody is formed in a process that pumps the analyte to the particle surface and employs temperature cycling to clear any unbound material from the particle surface. Unbound detection antibody, and therefore the fluorescent label, are removed by an appropriate washing step that allows the application of a non-fluorescent solution trapped inside the pNIPAM particles. After washing, the fluorescent signal associated with the particles is detected.

[0113] Detection antibody The cTnI detection antibody (clone 10C9, SDIX) is labeled and then purified using the Lightning-Link® R-Phycoerythrin Antibody Labeling Kit (Innova Bioscience) according to the manufacturer's protocol. Alternatively, fluorescently labeled antibodies may be obtained from a different supplier.

[0114] Capture antibody: Clone TPC-110 (SDIX) was used as the capture antibody, which was labeled with Lightning link streptavidin (Innova Bioscience) according to the manufacturer's protocol.

[0115] Preparation and recovery of pNIPAM detection particles Biotin-modified pNIPAM detection particles were prepared according to the method described in embodiment 1 with the following modifications: In an exemplary embodiment, biotin-labeled pNIPAM particles are transferred to the aqueous phase to eliminate inappropriate particle sizes, and then the particles are coated with a streptavidin-labeled capture antibody.

[0116] Coating pNIPAM detection particles with streptavidin-labeled capture antibodies Coating of pNIPAM with streptavidin-labeled capture antibodies is accomplished in PBS, 0.1% Triton X-100. The concentration of streptavidin-labeled capture antibodies is selected so that no accessible biotin remains on the surface of the pNIPAM particles (external or internal and external surfaces, depending on the pore width of the polymer). The optimal capture antibody concentration has been determined by determining the coverage of a flat surface in preliminary tests with labeled streptavidin. Coupling is done in an Eppendorf Thermoshaker, and the solution is agitated at 350 rpm for 30 min with 5 temperature oscillations between 25°C and 37°C. After coupling with the capture antibodies, the particles are pelleted as described above and washed several times by exchanging the supernatant. The concentration of pNIPAM-particles is then determined by counting under a microscope in a counting chamber.

[0117] Determining the appropriate concentration of detection antibody and generating a standard curve: Reaction mix: cTNI-depleted human EDTA-plasma + x μl cTNI spike 6 μl 500 mM phosphate buffer pH 7.5, 1 M NaCL, 0.25% Triton X-100 2 μl HBR-Plus (Scantibodies) 1 μl R-phycoerythrin-labeled detection antibody y μl pNIPAM detection particles coated with capture antibody z μl Total volume 10 μl

[0118] A number of such sets of reaction mixes should be set up to determine the appropriate concentration of the detection antibody and to assess the detection limit and dynamic range. Each set consists of reactions with different final cTNI concentrations. Typically, the cTNI concentrations in the reactions within each set vary from single digit pg / mL to double digit ng / mL final concentrations of cTNI and cTNI-free negative probe. The sets differ in the concentration of R-phycoerythrin-labeled detection antibody and / or the size and number of pNIPAM detection particles coated with capture antibody.

[0119] The reaction mix is ​​filled into a reaction vessel. This can be a capillary with a structure on one side, the dimensions of which are suitable to hide the particles as the liquid flows through it. This structure can be a sieve structure (like POREX), a step, etc. The capillary can also be a flexible tube, the dimensions and form of which can be modified by imposing an external mould on it. This also makes it possible to integrate the functionality of a valve.

[0120] The reaction vessel is placed on a Peltier element in direct contact with the heating / cooling element. In this sample, the Peltier was 30×30×4.7 mm, 19.3 W (Quick-Ohm, Kupper&Co. GmbH, no. QC-71-1.4-3.7M) allowing rapid temperature cycling. The sample was subjected to a temperature cycling protocol with the following parameters: Temperature 1: 37°C for 10 seconds Temperature 2: 25°C for 10 seconds.

[0121] 25 cycles.

[0122] The temperature is then set to 20° C. and the vessel is washed with 50 μl of washing buffer (50 mM phosphate buffer, pH 7.5, 100 mM NaCl, 0.05% Triton X-100). The particles are kept aside in the vessel.

[0123] The temperature cycling protocol is then applied again for 10 cycles. If necessary, the temperature is again set to 20° C. and the washing process is repeated.

[0124] For detection, the temperature is set to 37°C, which causes shrinkage of the pNIPAM detection particles and an enhancement of the fluorescence contrast. A digital image is taken of all particles. The fluorescence signal of each particle is measured and corrected for the local background. For the calibration curve, the median of all particle signals for each reaction mix in a set is plotted against the cTNI concentration of the sample.

[0125] The optimal concentration of labeled detection antibody and the optimal number and size of pNIPAM detection particles are indicated by the lowest detection limit and the widest dynamic measurement range.

[0126] Determining cTNI concentration in unknown samples: For each patient sample, the reaction mix is ​​composed as follows: Reaction mix: Human patient EDTA-plasma 6 μl 500 mM phosphate buffer, pH 7.5, 1 M NaCL, 0.25% Triton X-100 2 μl HBR-Plus (Scantibodies) 1 μl R-phycoerythrin labeled detection antibody x μl pNIPAM detection particles coated with capture antibody z μl Total volume 10 μl

[0127] The amount of detection antibody labeled with R-phycoerythrin (x) and the amount and size of the pNIPAM detection sensor body coated with the capture antibody (z) correspond to the optimal values ​​previously determined. The samples are incubated, temperature cycled, and washed as described above. The signal is measured by imaging as described above. Absolute cTNI values ​​can be calculated based on a separately generated calibration curve or based on spiked cTNI samples and negative controls assayed in parallel with the patient samples.

[0128] Example 3 Establishment of a fluorescence-based immunoassay using surface-immobilized spots as sensor bodies Here we describe a process to establish a fluorescence-based immunoassay for the detection of human cTnI using sensor bodies (i.e. sensor "spots") immobilized on a flat surface of a substrate. The assay employs a detection antibody labeled with a fluorescent dye. The capture antibody is labeled with streptavidin and coated onto a biotin-modified pNIPAM sensor matrix immobilized on a solid surface. A sandwich complex of the capture antibody, antigen and fluorescent detection antibody bound to the sensor matrix is ​​formed in a process that pumps the analyte to the sensor matrix surface and employs temperature cycling to strip any unbound material from the sensor matrix surface. Unbound detection antibody, and therefore the fluorescent label, are removed by an appropriate washing step that allows the application of a non-fluorescent solution that is trapped inside the pNIPAM sensor matrix. After washing, the fluorescent signal associated with the matrix is ​​detected.

[0129] Detection antibody The cTnI detection antibody (clone 10C9, SDIX) is labeled and then purified using the Lightning-Link® R-Phycoerythrin Antibody Labeling Kit (Innova Bioscience) according to the manufacturer's protocol.

[0130] Capture antibody: Clone TPC-110 (SDIX) was used as the capture antibody, which was labeled using the Lightning link streptavidin labeling kit (Innova Bioscience) according to the manufacturer's protocol.

[0131] Preparation of surface-immobilized pNIPAM sensor matrix spots Preparation of surface substrate: Borofloat glass microscope slides were used as substrates for immobilizing the sensor matrix spots. To allow for rigid immobilization of the sensor matrix to the surface, the surface was modified with PlusOne Bind-Silane (GE lifesciences) according to the manufacturer's protocol. Preparation of the polymerization mix: Mix 1, Aqueous Phase: [Table 8]

[0132] The mixes were degassed separately with four degass-purge cycles each and purged with argon, after which the mixes were kept in closed vials until use.

[0133] Spotting Mix 1 onto modified glass surfaces A piezoelectric printhead (MD-K-140-020) for fluids with a viscosity range of 0.4-10000 mPas and a nozzle diameter of 90 μm on a Microdrop / automated dispensing system (Microdrop Technologies) was used to produce spots of 180-380 pL. Substrates used included COC, polycarbonate, and glass slides.

[0134] Freshly prepared NIPAM solutions were filtered using a syringe through a Whatman® ReZist® syringe filter (30 mm, pore size 5 μm, PTFE) into a ND13 screw-neck vial. The heater and dispenser unit of the microdrop / automated dropper system were switched on and the system was cleaned by flushing it with filtered dH2O (or isopropanol). The nozzle temperature was adjusted to 23 °C and the system was activated by starting to fill the dispenser head three times for 5 seconds. The nozzle was wiped with 70% ethanol or isopropanol to remove larger drops. The dispensing parameters were as follows: the piezoelectric driving voltage ranged from 70 to 120 and the pulse length was between 30 and 50 μs. For the microdrop system, arrays were fabricated using a Steinmeyer XYZ-stage mounted under the dispenser head. Droplets were spotted onto the substrate at a frequency of 5 / sec in either burst or continuous mode ("on the fly").

[0135] To prevent the spots from drying out, the substrate was cooled to around the cloud point using a Quick-Ohm Peltier element (30×30×4.7 mm, 19.3 W, Kupper & Co. GmbH).

[0136] Polymerization and washing of slides After spotting, adhesive slide incubation chambers (BioRad) are attached to the slides. The chambers are suspended with Polymerization Mix 2 (oil phase) and incubated for 60 minutes.

[0137] After completing the polymerization process, the oil phase is removed from the chamber and the adhesive lid is removed. The slide is then placed in a 50 mL Falcon tube filled with PBS, 1% TritonX-100. The tube is gently swirled to remove most of the oil phase from the surface of the slide and spun briefly at 50 g to allow the oil phase to settle to the bottom of the tube. The slide is transferred to another tube filled with warm (40°C) PBS, 0.1% Triton and incubated for 1 min. The slide is then transferred to a new tube containing cold PBS, 0.1% Triton (15°C) and incubated for 2 min. The transfer from warm PBS, 0.1% Triton to cold PBS, 0.1% Triton is repeated 5 more times. Finally, the slide is washed twice with water and dried.

[0138] Coating of surface-attached pNIPAM sensor matrix with streptavidin-labeled capture antibodies Coating of pNIPAM with streptavidin-labeled capture antibodies is accomplished in phosphate-buffered saline (PBS), 0.1% Triton X-100. The concentration of streptavidin-labeled capture antibodies is selected so that no accessible biotin remains on the surface of the pNIPAM sensor matrix spots (external or internal and external surfaces, depending on the pore width of the polymer). The optimal capture antibody concentration has been determined by determining the coverage of a flat surface in preliminary tests with labeled streptavidin. For the coupling process, the slide is covered with an adhesive incubation chamber as used in the polymerization process. The chamber is filled with the streptavidin-labeled antibody solution and incubated on an Eppendorf thermoshaker in a microtiter plate adaptor with five temperature oscillations between 25 °C and 37 °C. After coupling with the capture antibodies, the sensor matrix spots are washed five times at 40 °C and 15 °C as described above. Slides can either be used directly in the assay or incubated in a solution containing 20 mg / mL trehalose with a final washing step at 15° C. and then lyophilized before use in the assay. Determining the appropriate concentration of detection antibody and generating a standard curve: Reaction mix: cTNI-depleted human EDTA-plasma + x μl cTNI spike 60 μl 500 mM phosphate buffer, pH 7.5, 1 M NaCL, 0.25% Triton X-100 20 μl HBR-Plus (Scantibodies) 10 μl R-phycoerythrin-labeled detection antibody y μl Total volume 100 μl

[0139] A number of such sets of reaction mixes should be set up to determine the appropriate concentration of the detection antibody and to assess the detection limit and dynamic range. Each set consists of reactions with different final cTNI concentrations. Typically, the cTNI concentrations in the reactions within each set vary from single digit pg / mL to double digit ng / mL final concentrations of cTNI and cTNI-free negative probe. The sets differ in terms of the concentration of the R-phycoerythrin-labeled detection antibody.

[0140] For incubation with the analyte mix, the slide is covered with an incubation chamber as used in the previous polymerization step. 65 μl of reaction mix is ​​filled into the chamber and the chamber is closed.

[0141] The slide, with the area containing the sensor matrix spots, is placed on a Peltier element in direct contact with the heating / cooling element. In this sample, the Peltier was 30x30x4.7mm, 19.3W (Quick-Ohm, Kupper&Co. GmbH, no. QC-71-1.4-3.7M) capable of rapid temperature cycling. The sample was subjected to a temperature cycling protocol with the following parameters: Temperature 1: 37℃ for 10 seconds Temperature 2: 10 seconds at 25℃ 25 cycles.

[0142] The temperature is then set to 20° C., the incubation mix is ​​removed, and the incubation chamber is washed several times with wash buffer (50 mM phosphate buffer, pH 7.5, 100 mM NaCl, 0.05% Triton X-100). The final wash volume is maintained in the chamber and the 10 cycle temperature cycling protocol is applied once more. If necessary, the wash process can be repeated several times, with the wash fluid being replaced for each additional wash process.

[0143] For detection, the temperature is set to 37°C, which causes contraction of the pNIPAM sensor matrix and an enhancement of the fluorescence contrast. A digital image is taken of the area containing the sensor matrix spots. The fluorescence signal of each sensor matrix spot is measured and corrected for the local background. For the calibration curve, the median of all sensor matrix spot signals for each reaction mix in a set is plotted against the cTNI concentration of the sample.

[0144] The optimal concentration of labeled detection antibody is indicated by the lowest detection limit and the widest dynamic measurement range.

[0145] Determining cTNI concentration in unknown samples: For each patient sample, the reaction mix is ​​composed as follows: Reaction mix: Human patient EDTA-plasma 60 μl 500 mM phosphate buffer, pH 7.5, 1 M NaCl, 0.25% Triton X-100 20 μl HBR-Plus (Scantibodies) 10 μl R-phycoerythrin-labeled detection antibody x μl Total volume 100 μl

[0146] The amount (x) of detection antibody labeled with R-phycoerythrin corresponds to the optimal value previously determined. Samples are incubated, temperature cycled, and washed as described above. Signals are measured by imaging as described above. Absolute cTNI values ​​can be calculated based on a standard curve created separately or based on spiked cTNI samples and negative controls assayed in parallel with patient samples.

[0147] Example 4 Establishment of a combined target capture / real-time target amplification assay using biotin-modified pNIPAM-based Giant Amplification Beads (GABs) Generation of polymerization mix for biotin-modified / unmodified pNIPAM particles to perform PCR with giant amplification beads (GAB) Component 1 (aqueous phase): Preparation of biotin-modified monomer-mix:

[0148] Biotin-modified acrylic acid monomers were made in separate reactions: the reaction mix consisted of acrylic acid N-hydroxysuccinimide ester (an activated amino-reactive acrylic acid monomer) and biotin-dPEG7-NH2 (a biotin derivative modified with a PEG7 spacer arm terminated in an ammino group). [Table 9]

[0149] The reaction mix was incubated for 30 minutes at 25° C. This mix was used for the pNIPAM polymerization reaction without any further purification. Components per mL of Polymerization Mix [Table 10] Component 2 (Oily Phase): [Table 11]

[0150] The mixes were each separately degassed with four degass-purge cycles and purged with argon, after which 50 μl aliquots of component 2 were placed into each tube of an 8-well PCR tube strip.

[0151] A 2 μl aliquot of component 1 was then pipetted into each of the tubes. The droplets were allowed to polymerize for 60 min at room temperature. The use of mixes 1 and 2 results in particles ("beads", "bodies") consisting of approximately 10% cross-linked pNIPAM gel. Mixes 3 and 4 result in particles consisting of approximately 5% cross-linked pNIPAM gel. Mixes 1 and 3 do not contain biotin-modified monomers, while mixes 2 and 4 contain biotin-modified monomers. The 5% pNIPAM gel shows a larger pore width compared to the 10% pNIPAM gel. The percentage of gel and cross-linking can be varied.

[0152] Particle recovery and transfer to the aqueous phase After completing the polymerization process, each sample was diluted with 100 μl of HO. 2 2. Add 100 μl of HO. The pNIPAM particles can be transferred to the aqueous phase and the hexadecane supernatant can be removed. To remove residual unpolymerized reagents and TEMED, the particles are heated to 50° C. to facilitate shrinkage to drive the liquid from the particles. Excess liquid is removed and 100 μl of HO is added. 2 O is added. Upon cooling, H 2 O is absorbed by the expanding particles. Heating, removal of liquid, and new H 2 The washing cycle, which included the addition of O and cooling, was repeated twice. 2 The O was replaced with PBS containing 0.1% Triton X100.

[0153] Coating of GAB with streptavidin Coating of the GAB with streptavidin is accomplished in the previously used washing buffer. The streptavidin concentration is chosen such that no accessible biotin remains on the surface of the GAB. In any case, the streptavidin is applied in excess to avoid cross-linking of the GAB. The optimal streptavidin concentration has been determined in preliminary tests with labeled streptavidin by determining the coverage of a flat surface. Particles made with mixes 2 and 4 were incubated with a solution of streptavidin in PBS containing 0.1% Triton X-100. Particles made with mixes 1 and 3 (without biotin modification) were incubated with the same solution as a negative control. After coupling with streptavidin, the GAB is washed three times with 100 μl of PBS containing 0.1% Triton X-100 to remove excess streptavidin. Incubation Mix: [Table 12]

[0154] Application of GAB to perform PCR Preparation of biotinylated HIV-1 cDNA Biotinylated HIV-1 cDNA was generated by performing reverse transcription in the presence of a biotinylated reverse primer. The reaction mix was incubated at 50°C for 15 min and the reaction was stopped by heating the reaction mix to 70°C for 10 min. Incubation Mix: - Purified HIV-1 RNA (approximately 10 6 copy) - 1 μM biotinylated reverse primer, 5'biotin-ACT GAC GCT CTC GCA CCC ATC T-3' - 1x Reaction Buffer (cDNA Synthesis Kit, Thermo Fisher) - dNTP (1mM each) - RevertAid Reverse Transcriptase (200U, Thermo Fisher)

[0155] The cDNA reaction mix was diluted with PBS, 0.1% Triton X-100 to a final concentration of approximately 10 4 Convert to cp / μl.

[0156] Enrichment of HIV-1 cDNA targets on GAB and incubation of the beads with amplification mix HIV-1 RNA, labeled with biotin by reverse transcription, is enriched on streptavidin-modified giant amplification beads (GAB). Incubation mix per particle: - 1 μl of cDNA mix (approximately 10 4 copy) - 49 μl PBS containing 0.1% Triton X-100

[0157] The GAB is heated to 50°C to drive the liquid phase from the particles. The liquid is removed, incubation mix is ​​added, and the GAB is allowed to cool. The mix is ​​heated three times to 50°C (to contract) and cooled to room temperature (to expand), with mixing in between, to facilitate binding of the biotinylated cDNA to the streptavidin-labeled GAB. Finally, the GAB is heated to 50°C and excess liquid is removed.

[0158] The PCR reaction mix is ​​then added at room temperature and the particles are heated to 50 °C and cooled again to facilitate the incorporation of the PCR mix. Excess liquid is removed at room temperature and the GAB is covered with 25 µl of mineral oil to prevent evaporation during the PCR reaction.

[0159] The PCR mix consists of the following reagents (final concentrations): - 6mM Mg 2+ , 20 mM Tris-HCl, pH 8.9, 22 mM KCl, 22 mM NH 4 1x PCR buffer containing Cl, 5% glycerol, 0.01% Triton-X100 and 0.005% Tween 20, 1mg / ml sodium polyphosphate - 400μM dNTPs (Invitrogen) - 0.8 μM forward primer: 5'-GCA GTG GCG CCC GAAC AGG-3' (Metabion international AG) - 0.8 μM reverse primer: 5'-ACT GAC GCT CTC GCA CCC ATC T-3' (Metabion international AG) - 0.8 μM hybridization probe: 5'-Cy5-CTC CGA CGC AAC GGG CTC G-BHQ3-3' - Lyophilized hot-start Taq DNA polymerase (BiotechRabbit), 0.125U / μl

[0160] Alternatively, HIV-1 RNA can be enriched on streptavidin-labeled GAB without prior cDNA synthesis by incubating a sample containing HIV-RNA with a suitable mixture of complementary capture oligonucleotides labeled with biotin as described by Bruns and Steinmetzer [8]. A reverse transcription step is then carried out as part of real-time reverse transcription PCR (rt RT-PCR) using the reverse transcriptase enzyme included in the RT-PCR mix as described therein.

[0161] Amplification reaction in GAB PCR can be performed in any standard real-time cycler. The conditions listed below apply to the PeqSTAR96Q. The applied heating conditions are as follows:

[0162] Initial denaturation at 95°C for 2 min, followed by 5 cycles of denaturation at 95°C for 15 s, annealing at 65°C for 30 s and extension at 72°C for 30 s. Then 40 cycles of denaturation at 95°C for 15 s, annealing at 65°C for 20 s and extension at 72°C for 30 s are performed. Amplification within GAB is monitored in real time using standard Cy5 detector settings. After a total of 45 PCR cycles, the positive control showed a ct-value of 19.5 (SD 0.84, N=12) whereas the negative control showed no amplification signal.

[0163] Example 5 Application of pNIPAM-based monodisperse digital amplification beads (DAB) to perform digital PCR Here we describe the use of pNIPAM-based digital amplification beads (DAB) to perform digital PCR. In this application, DAB simply provides a matrix that can be filled with an aqueous solution and easily emptied using the LCST behavior of the pNIPAM polymer. This polymer also provides a matrix that allows the aqueous phase contained in the particles to be brought into the oil emulsion. The advantage of using DAB as a matrix is ​​that a uniform size distribution of the water volume in the oil can be achieved without the need to use microfluidics or other complex technical devices. In this experiment, cDNA, generated in a separate step, was used as the PCR template. When using RNA as a template, the particles can be filled with the RT-PCR reaction mix and the entire process of the RT-PCR process can be carried out on a DAB basis. Generation of pNIPAM particle polymerization mix for digital PCR Component 1 (aqueous phase): Components per mL of Polymerization Mix [Table 13] Component 2 (Oily Phase): [Table 14]

[0164] The mixes were degassed separately with four degass-purge cycles each and purged with argon. The mixes were then pipetted into the respective wells of a BioRad droplet generator chip DG8 under argon atmosphere. 60 μl of the oil phase was placed in each oil phase reservoir and 25 μl of the aqueous phase was placed in each aqueous phase reservoir.

[0165] BioRad's protocol for droplet generation was then followed (QX200™ Droplet Generator Instructions Manual 10031907 RevC). Alternatively, the chip could also be operated manually. For that purpose, a 50 mL syringe needs to be connected to the droplet reservoir of the droplet generator chip by means of a tube and a suitable adapter. Before connecting, the plunger is set to the 30 mL position. After filling the aqueous and oil phases, the plunger is manually extended to the 50 mL position to apply a predefined pressure to the system. Just before the oil or aqueous phase reservoir is empty, the pressure is released.

[0166] The droplet reservoir was covered with adhesive tape. The droplets were allowed to polymerize for 60 min at room temperature. This reaction results in particles consisting of approximately 5% pNIPAM gel that is cross-linked. The percentage of gel and cross-linking can be varied.

[0167] Particle recovery and transfer to the aqueous phase After completing the polymerization process, gently withdraw as much of the oil phase as possible from the droplet reservoir using a pipette, taking care not to remove the pNIPAM particles. Then, pipette 50 μl of 1% (v / v) Triton X-100 in water onto the particles. Mix the contents by pipetting up and down to prevent the particles from sticking to the walls of the droplet tip. Transfer the contents to an Eppendorf tube and repeat this process one more time. The transfer process can be monitored under a binocular microscope to ensure that most of the particles are not lost in this step.

[0168] The tube is then centrifuged at 2000g for 1 minute. The oil phase (bottom) and the aqueous phase (top) are now well separated, with the particles contained between them. 200 μl of density gradient medium (Optiprep, Axis shield) are now slowly pipetted into the tube. It is important to avoid excessive mixing of the aqueous phase with the density gradient medium. Ideally, most of the density gradient medium will be under the particle phase. The tube is centrifuged at 2000g for 2 minutes. The density gradient medium phase is then located between the oil phase and the particle phase. The particle phase may now be transferred to a new tube. At this step, care must be taken not to transfer any oil volume to the new tube, and to keep the density gradient medium volume as small as possible.

[0169] 1 mL of PBS, 0.1% (v / v) Triton X-100 is added to the tube containing the particles. The contents are mixed and centrifuged at 2000 g for 2 min. The particles are now pelleted at the bottom of the tube. The supernatant is removed, leaving the particles in the tube. 1 mL of PBS, 0.1% (v / v) Triton X-100 is added again to the tube and the washing process is repeated 5 times. Finally, the particles are dissolved in water containing 0.01% Triton X-100. The concentration of DAB is then determined by counting under a microscope in a DHC-N01 (Neubauer Modified) counting chamber (INCYTO) or by hemocytometry on a CytoFlex flow cytometer (Beckman Coulter).

[0170] Preparation of HIV-1 cDNA template HIV-1 cDNA was generated by performing reverse transcription in the presence of PCR reverse primer. The reaction mix was incubated at 50° C. for 15 min and the reaction was stopped by heating the reaction mix to 70° C. for 10 min. Incubation Mix: - Purified HIV-1 RNA (approximately 10 6 copy) - 1 μM of reverse primer 5' ACT GAC GCT CTC GCA CCC ATC T-3' - 1x Reaction Buffer (cDNA Synthesis Kit, Thermo Fisher) - dNTP (1mM each) - RevertAid Reverse Transcriptase (200U, Thermo Fisher)

[0171] The cDNA reaction mix was diluted with PBS, 0.1% Triton X-100 to a final concentration of approximately 10 4 Convert to cp / μl.

[0172] Loading of pNIPAM-based DAB in the amplification mix Approximately 100,000 pNIPAM DAB were transferred to a reaction tube and heated to 50° C. to drive the liquid phase from the particles. The particles were briefly spun at 2000 g and held at 40° C. The shrunken pelleted particles tightly stuck together, forming a solid mass, allowing the driven liquid to be completely removed from the pellet.

[0173] A PCR amplification mix of 10 μl containing 1000 copies of HIV cDNA was made up. The volume of the amplification mix must be smaller than the volume that the particles can absorb. This depends mainly on the number and size of the particles. In this example, the particles used were able to absorb a volume of 12 μl. The mix consists of the following reagents (final concentrations): - 6mM Mg 2+ , 20 mM Tris-HCl, pH 8.9, 22 mM KCl, 22 mM NH 4 1x PCR buffer containing Cl, 5% glycerol, 0.01% Triton-X100 and 0.005% Tween 20, 1mg / ml sodium polyphosphate - 400μM dNTPs (Invitrogen) - 0.8 μM forward primer: 5'-GCA GTG GCG CCC GAAC AGG-3' (Metabion international AG) - 0.8 μM reverse primer: 5'-ACT GAC GCT CTC GCA CCC ATC T-3' (Metabion international AG) - 0.8 μM hybridization probe: 5'-CF647-CTC CGA CGC AAC GGG CTC G-BHQ3-3' - 1000 copies of HIV-1 cDNA template - Lyophilized hot-start Taq DNA polymerase (BiotechRabbit), 0.125U / μl

[0174] This mix was applied to the particle pellet and incubated at 20° C. At this temperature, the particles swell and absorb the entire volume of the PCR reaction mix.

[0175] Compartmentalization of DAB by dispersing it in oil Microcompartments with a defined volume are made by dispersing DAB in fluorocarbon oil, for example PicoSurf™ 5% dispersed in Novec 7500 oil (Dolomite Microfluidics, no. 3200214). Instead of heavy fluorocarbon oil, light oil containing emulsifier may be applied, for example mineral oil (Sigma-Aldrich, no. M5904 Sigma) containing 5% (w / w) Span 80 (Sigma Aldrich, no. 85548).

[0176] The particle pellet is contacted with an excess of oil in an Eppendorf tube. Ultrasonication is applied until the DAB pellet is dispersed and the DAB is evenly distributed. The pNIPAM DAB loaded with the HIV-1 cDNA target is now emulsified in the oil phase. The oil containing the DAB is added to approximately 2 cm 2The beads are transferred to a detection chamber with an area of ​​100 nm and a layer thickness of approximately 1 mm. The opposite side of the chamber is made of a transparent hydrophobic material. If fluorocarbon oil is used, the DAB assemble as a monolayer (dense packing) on ​​the hydrophobic upper surface due to the density difference between the beads and the oil. If mineral oil is applied, the DAB is expected to accumulate on the lower surface. The DAB thus provides a micro-reaction container for the subsequent digital PCR.

[0177] Amplification reactions in DAB microcompartments The DAB suspended in oil is subjected to temperature cycling in the same chamber on a Peltier element 30x30x4.7mm, 19.3W (Quick-Ohm, Kupper&Co. GmbH, no. QC-71-1.4-3.7M). When heated above 32°C, the DAB is concentrated such that the reaction mix inside the DAB is expelled. This forms a single aqueous droplet around the periphery of the concentrated DAB that serves as the micro-reaction compartment in which the amplification of individual cDNA molecules takes place.

[0178] The applied heating conditions are as follows: Initial denaturation at 95°C for 2 min, followed by 45 cycles of denaturation at 95°C for 15 s, annealing at 65°C for 15 s and extension at 72°C for 30 s. Once the thermal protocol is complete, the chamber contents are imaged at 21°C in fluorescence mode with transmitted white light and excitation λexc=650 nm and long pass emission >670 nm. The total number of DABs and the number of DABs with a fluorescent signal above a predefined intensity threshold are determined. The threshold is obtained from a template-free amplification reaction performed previously. The number of templates in the reaction is determined by applying Poisson statistics to the determined number of positive and negative droplets.

[0179] Example 6 Application of biotin-modified pNIPAM-based monodisperse amplification beads (DAB) to perform a combined target capture / digital PCR assay This example describes the use of pNIPAM-based digital amplification beads (DABs) (= "sensor bodies" according to embodiments of the present invention) to perform a combined nucleic acid target capture / digital PCR assay. In this application, the DABs provide a number of functional groups.

[0180] 1. They provide binding groups and an exterior or interior and exterior surface for capturing the assay target at the location where amplification is expected to occur in a further step.

[0181] 2. They provide a matrix that can be filled with aqueous solutions and easily emptied by taking advantage of the LCST behavior of the pNIPAM polymer.

[0182] 3. The polymer also provides a matrix that allows the aqueous phase contained in the particles to be brought into the oil emulsion. The advantage of using DAB as a matrix is ​​that a uniform size distribution of the water volume in the oil can be achieved without the need to use microfluidics or other complex technological devices.

[0183] In this experiment, cDNA generated in a separate step was used as the PCR template. If RNA is used as the template, the particles can be filled with the RT-PCR reaction mix and the entire process of the RT-PCR process can be carried out on a DAB basis.

[0184] Generation of pNIPAM particle polymerization mix for digital PCR Component 1 (aqueous phase): Preparation of biotin-modified monomer mix: Biotin-modified acrylic acid monomers were made in separate reactions: the reaction mix consisted of acrylic acid N-hydroxysuccinimide ester (an activated amino-reactive acrylic acid monomer) and biotin-dPEG7-NH2 (a biotin derivative modified with an amino-terminated PEG7 spacer arm). [Table 15]

[0185] The reaction mix was incubated for 30 minutes at 25° C. This mix was used for the pNIPAM polymerization reaction without any further purification. Components per mL of Polymerization Mix [Table 16] Component 2 (Oily Phase): [Table 17]

[0186] The mixes were degassed separately with four degass-purge cycles each and purged with argon. The mixes were then pipetted into the respective wells of a BioRad droplet generator chip DG8 under argon atmosphere. 60 μl of the oil phase was placed in each oil phase reservoir and 25 μl of the aqueous phase was placed in each aqueous phase reservoir.

[0187] BioRad's protocol for droplet generation was then followed (QX200™ Droplet Generator Instructions Manual 10031907 RevC). Alternatively, the chip could also be operated manually. For that purpose, a 50 mL syringe needs to be connected to the droplet reservoir of the droplet generator chip by means of a tube and a suitable adapter. Before connecting, the plunger is set to the 30 mL position. After filling the aqueous and oil phases, the plunger is manually extended to the 50 mL position to apply a predefined pressure to the system. Just before the oil or aqueous phase reservoir is empty, the pressure is released.

[0188] The droplet reservoir was covered with adhesive tape. The droplets were allowed to polymerize for 60 min at room temperature. The use of Mix 1 results in particles consisting of about 10% pNIPAM gel cross-linked. Mix 2 results in particles consisting of about 5% pNIPAM gel cross-linked. The latter shows a larger pore width compared to the former. The percentage of gel and cross-linking can be varied.

[0189] Collection of particles ("bodies") and transfer to the aqueous phase After completing the polymerization process, gently withdraw as much of the oil phase as possible from the droplet reservoir using a pipette, taking care not to remove the pNIPAM particles. Then, pipette 50 μl of 1% (v / v) Triton X-100 in water onto the particles. Mix the contents by pipetting up and down to prevent the particles from sticking to the walls of the droplet tip. Transfer the contents to an Eppendorf tube and repeat this process one more time. The transfer process can be monitored under a binocular microscope to ensure that most of the particles are not lost in this step.

[0190] The tube is then centrifuged at 2000g for 1 minute. The oil phase (bottom) and the aqueous phase (top) are now well separated, with the particles contained between them. 200 μl of density gradient medium (Optiprep, Axis shield) are now slowly pipetted into the tube. It is important to avoid excessive mixing of the aqueous phase with the density gradient medium. Ideally, most of the density gradient medium will be under the particle phase. The tube is centrifuged at 2000g for 2 minutes. The density gradient medium phase is then located between the oil phase and the particle phase. The particle phase may now be transferred to a new tube. At this step, care must be taken not to transfer any oil volume to the new tube, and to keep the density gradient medium volume as small as possible.

[0191] 1 mL of PBS, 0.1% (v / v) Triton X-100 is added to the tube containing the particles. The contents are mixed and centrifuged at 2000 g for 2 minutes, where the particles are pelleted at the bottom of the tube. The supernatant is removed, leaving the particles in the tube. 1 mL of PBS, 0.1% (v / v) Triton X-100 is added again to the tube, and the washing process is repeated 5 times. Finally, the particles are dissolved in PBS with 0.1% Triton X-100.

[0192] Coating of DAB with streptavidin Coating of the DAB with streptavidin is accomplished in the previously used washing buffer. The concentration of streptavidin is selected so that no accessible biotin remains on the surface of the DAB. In any case, the streptavidin is applied in an excess amount to avoid cross-linking of the DAB. The optimal streptavidin concentration has been determined by determining the coverage of a flat surface in preliminary tests with labeled streptavidin. Incubation Mix: [Table 18]

[0193] The coupling is done in an Eppendorf thermoshaker and the solution is agitated at 350 rpm for 30 min with 5 temperature oscillations between 25°C and 37°C. After coupling with streptavidin, the DAB is washed to remove excess streptavidin. 1 mL of PBS, 0.1% (v / v) Triton X-100 is added to the tube containing the particles. The contents are mixed and the temperature is set to 40°C. The particles shrink and the internal liquid is expelled. The particles are then centrifuged at 2000g and 40°C for 2 min. Now the particles are pelleted at the bottom of the tube. The supernatant is removed, leaving the particles in the tube. 1 mL of 20°C PBS, 0.1% (v / v) Triton X-100 is added to the tube. The particles swell and absorb the washing buffer. The contents are mixed and the temperature is set again to 40°C. This washing process is repeated 5 times. Finally, the particles are dissolved in water containing 0.01% Triton X-100. The concentration of DAB is then determined by counting under a microscope in a DHC-N01 (Neubauer Modified) counting chamber (INCYTO) or by hemocytometry on a CytoFlex flow cytometer (Beckman Coulter).

[0194] Preparation of HIV-1 cDNA template Biotinylated HIV-1 cDNA was generated by performing reverse transcription in the presence of PCR reverse primer. The reaction mix was incubated at 50° C. for 15 min and the reaction was stopped by heating the reaction mix to 70° C. for 10 min. Incubation Mix: - Purified HIV-1 RNA (approximately 10 6 copy) - 1 μM biotinylated reverse primer 5'biotin-ACT GAC GCT CTC GCA CCC ATC T-3' - 1x Reaction Buffer (cDNA Synthesis Kit, Thermo Fisher) - dNTP (1mM each) - RevertAid Reverse Transcriptase (200U, Thermo Fisher)

[0195] The cDNA reaction mix was diluted with PBS, 0.1% Triton X-100 to a final concentration of approximately 10 4 Convert to cp / μl.

[0196] Capture of HIV-1 cDNA targets on DAB HIV-1 RNA labeled with biotin by reverse transcription is captured on a streptavidin-modified DAB. Approximately 100,000 pNIPAM DAB are transferred to a reaction tube and heated to 50°C to expel the liquid phase from the particles. The particles are briefly spun at 2000g and held at 40°C. The shrunken pelleted particles become tightly packed together, allowing the expelled liquid to be completely removed from the pellet. The following incubation mix is ​​then added to the pellet: - 1 μl of cDNA mix (approximately 10 4 copy) - 49 μl PBS containing 0.1% Triton X-100

[0197] The capture was performed in an Eppendorf thermoshaker, the solution being agitated at 350 rpm for 30 min with 5 temperature oscillations between 25° C. and 37° C.

[0198] Loading of pNIPAM-based DAB in the amplification mix After target capture, the DAB is heated to 50° C. to drive the liquid phase from the particles. The particles are briefly spun at 2000 g and held at 40° C. The shrunken pelletized particles become tightly packed together, allowing the driven liquid to be completely removed from the pellets.

[0199] A PCR amplification mix of 10 μl without template was made up. The volume of the amplification mix must be smaller than the volume that the particles can absorb. This depends mainly on the number and size of the particles. In this example, the particles used were able to absorb a volume of 12 μl. The amplification mix consists of the following reagents (final concentrations): - 6mM Mg 2+ , 20 mM Tris-HCl, pH 8.9, 22 mM KCl, 22 mM NH 4 1x PCR buffer containing Cl, 5% glycerol, 0.01% Triton-X100 and 0.005% Tween 20, 1mg / ml sodium polyphosphate - 400μM dNTPs (Invitrogen) - 0.8 μM forward primer: 5'-GCA GTG GCG CCC GAAC AGG-3' (Metabion international AG) - 0.8 μM reverse primer: 5'-ACT GAC GCT CTC GCA CCC ATC T-3' (Metabion international AG) - 0.8 μM hybridization probe: 5'-CF647-CTC CGA CGC AAC GGG CTC G-BHQ3-3' - Lyophilized hot-start Taq DNA polymerase (BiotechRabbit), 0.125U / μl

[0200] This mix was applied to the particle pellet and incubated at 20° C. At this temperature, the particles swell and absorb the entire volume of the PCR reaction mix.

[0201] Compartmentalization of DAB by dispersing it in oil Microcompartments with a defined volume are made by dispersing DAB in fluorocarbon oil, for example PicoSurf™ 5% dispersed in Novec 7500 oil (Dolomite Microfluidics, no. 3200214). Instead of heavy fluorocarbon oil, light oil containing emulsifier may be applied, for example mineral oil (Sigma-Aldrich, no. M5904 Sigma) containing 5% (w / w) Span 80 (Sigma Aldrich, no. 85548).

[0202] The particle pellet is contacted with an excess of oil in an Eppendorf tube. Ultrasonication is applied until the DAB pellet is dispersed and the DAB is evenly distributed. The pNIPAM DAB loaded with the HIV-1 cDNA target is now emulsified in the oil phase. The oil containing the DAB is added to approximately 2 cm 2 The beads are transferred to a detection chamber with an area of ​​100 nm and a layer thickness of approximately 1 mm. The opposite side of the chamber is made of a transparent hydrophobic material. If fluorocarbon oil is used, the DAB assemble as a monolayer (dense packing) on ​​the hydrophobic upper surface due to the density difference between the beads and the oil. If mineral oil is applied, the DAB is expected to accumulate on the lower surface. The DAB thus provides a micro-reaction container for the subsequent digital PCR.

[0203] Amplification reactions in DAB microcompartments The DAB suspended in oil is subjected to temperature cycling in the same chamber on a Peltier element 30x30x4.7mm, 19.3W (Quick-Ohm, Kupper&Co. GmbH, no. QC-71-1.4-3.7M). When heated above 32°C, the DAB is concentrated such that the reaction mix inside the DAB is expelled. This forms a single aqueous droplet around the periphery of the concentrated DAB that serves as the micro-reaction compartment in which the amplification of individual cDNA molecules takes place. The applied heating conditions are as follows:

[0204] Initial denaturation at 95°C for 2 min, followed by 45 cycles of denaturation at 95°C for 15 s, annealing at 65°C for 15 s and extension at 72°C for 30 s. Once the thermal protocol is complete, the chamber contents are imaged at 21°C in fluorescence mode with transmitted white light and excitation λexc=650 nm and long pass emission >670 nm. The total number of DABs and the number of DABs with a fluorescent signal above a predefined intensity threshold are determined. The threshold is obtained from a template-free amplification reaction performed previously. The number of templates in the reaction is determined by applying Poisson statistics to the determined number of positive and negative droplets.

[0205] Example 7 Application of biotin-modified pNIPAM-based monodisperse digital amplification beads (DAB) to establish digital Elisa Here we describe a process to establish a digital immunoassay for the detection of human cTnI. The assay employs immunoPCR in a digital manner, and the detection antibody is labeled with DNA. The capture antibody is labeled with streptavidin and coated onto biotin-modified pNIPAM particles. A sandwich complex of the particles bound with the capture antibody, antigen and DNA-labeled detection antibody is formed in a process that pumps the analyte to the particle surface and employs temperature cycling to clear any unbound material from the particle surface. Unbound detection antibody and therefore DNA label are removed by an appropriate washing step that employs temperature cycling. The pNIPAM-based DAB is loaded with PCR amplification mix and suspended in oil so that separate reaction compartments are formed. Subsequent droplet PCR detects the bound DNA-label.

[0206] Detection antibody The cTnI detection antibody (clone 10C9, SDIX) is labeled and then purified using the Thunder-Link® PLUS Oligo Conjugation System (Innova Bioscience) according to the manufacturer's protocol. The following sequence is coupled to the antibody: [ka]

[0207] Capture antibody: Clone TPC-110 (SDIX) was used as the capture antibody, which was marked with Lightning link streptavidin (Innova Bioscience) according to the manufacturer's protocol.

[0208] Preparation and recovery of pNIPAM detection particles Biotin-modified pNIPAM detection particles were prepared according to the method described in embodiment 1 with the following modifications: In an exemplary embodiment, biotin-labeled pNIPAM particles are transferred to the aqueous phase to eliminate inappropriate particle sizes, and then the particles are coated with a streptavidin-labeled capture antibody.

[0209] Coating pNIPAM detection particles with streptavidin-labeled capture antibodies Coating of pNIPAM with streptavidin-labeled capture antibody is accomplished in PBS, 0.1% Triton X-100. The concentration of streptavidin-labeled capture antibody is selected such that the appearance of false positive signals is minimized and good sensitivity is achieved. The optimal capture antibody concentration has been determined in preliminary tests (see below). Coupling is performed in an Eppendorf thermoshaker, and the solution is agitated at 350 rpm for 30 min with 5 temperature oscillations between 25°C and 37°C. After coupling with the capture antibody, the particles are pelleted as described above and washed several times by exchanging the supernatant. The concentration of pNIPAM-particles is then determined by counting under a microscope in a counting chamber. The concentration of the particles is adjusted to approximately 5,000 / μl. The particles are aliquoted in 20 μl increments.

[0210] Optimize antibody concentration: The optimal concentration of particles coupled with DNA label detection and capture antibodies was determined by conventional immuno-PCR. The concentrations of the two antibodies were systematically varied to generate immune complexes using troponin-free plasma (negative control) and troponin-free plasma with a defined amount of spiked troponin I. These were captured on particles, washed, and subjected to conventional PCR. The optimal concentration of each antibody is indicated by the lowest detection limit and the widest dynamic measurement range. Formation of immune complexes and their capture: Reaction mix: Human EDTA-plasma 50 μl 500 mM phosphate buffer, pH 7.5, 1 M NaCL, 0.25% Triton X-100 20 μl HBR-Plus (Scantibodies) 10 μl DNA-labeled detection antibody y μl pNIPAM detection particles coated with capture antibody 20 μl Total volume approx. 100 μl

[0211] Immune complex generation and capture and washing: Approximately 100 μl of reaction mixture (see above) is prepared using the optimal concentrations determined so far. The capture is done in an Eppendorf thermoshaker, the solution is agitated at 350 rpm for 30 min with 5 temperature oscillations between 25° C. and 37° C. After capture, the DAB is washed to remove non-specifically bound detection antibodies. 1 mL of PBS, 0.1% (v / v) Triton X-100 is added to the tube containing the particles. The contents are mixed and the temperature is set to 40° C. The particles shrink and the internal liquid is expelled. The particles are then centrifuged for 2 min at 2000 g and 40° C., where they are pelleted at the bottom of the tube. The supernatant is removed, leaving the particles in the tube. 1 mL of 20° C. PBS, 0.1% (v / v) Triton X-100 is added to the tube. The particles swell and absorb the wash buffer. The contents are mixed and the temperature is again set to 40° C. This washing process is repeated several times until the false positive signal is within a range that allows a lower level of quantification to be reached (determined experimentally). Two additional washing steps with 1× Taq DNA polymerase PCR buffer [20 mM Tris-HCl (pH 8.4), 50 mM KCl] are then performed.

[0212] Loading of pNIPAM-based DAB in the amplification mix After target capture, the DAB is heated to 50° C. to drive the liquid phase from the particles. The particles are briefly spun at 2000 g and held at 40° C. The shrunken pelletized particles become tightly packed together, allowing the driven liquid to be completely removed from the pellet.

[0213] A template-free PCR amplification mix of 10 μl was made up. The volume of the amplification mix must be smaller than the volume that the particles can absorb. This depends mainly on the number and size of the particles. In this example, the particles used were able to absorb a volume of 14 μl. The amplification mix consists of the following reagents (final concentrations): Prepare a PCR reaction mixture (volume 10 μl) with the following composition: 500 nM forward primer (5'AGCTCTTGATCCGGCAAACA3') 500 nM reverse primer (5'GCGTCAGACCCCGTAGAAAA3') SYBR® Green I Nucleic Acid Gel Stain (Sigma-Aldrich, No. S9430) 1:25000 1x PCR-Master Mix PCR-grade water

[0214] This mix was applied to the particle pellet and incubated at 20° C. At this temperature, the particles swell and absorb the entire volume of the PCR reaction mix.

[0215] Compartmentalization of DAB by dispersing it in oil Microcompartments with a defined volume are made by dispersing DAB in fluorocarbon oil, for example PicoSurf™ 5% dispersed in Novec 7500 oil (Dolomite Microfluidics, no. 3200214). Instead of heavy fluorocarbon oil, light oil containing emulsifier may be applied, for example mineral oil (Sigma-Aldrich, no. M5904 Sigma) containing 5% (w / w) Span 80 (Sigma Aldrich, no. 85548).

[0216] The particle pellet is contacted with an excess of oil in an Eppendorf tube. Ultrasonication is applied until the DAB pellet is dispersed and the DAB is evenly distributed. The pNIPAM DAB loaded with the HIV-1 cDNA target is now emulsified in the oil phase. The oil containing the DAB is added to approximately 2 cm 2 The beads are transferred to a detection chamber with an area of ​​100 nm and a layer thickness of approximately 1 mm. The opposite side of the chamber is made of a transparent hydrophobic material. If fluorocarbon oil is used, the DAB assemble as a monolayer (dense packing) on ​​the hydrophobic upper surface due to the density difference between the beads and the oil. If mineral oil is applied, the DAB is expected to accumulate on the lower surface. The DAB thus provides a micro-reaction container for the subsequent digital PCR.

[0217] Amplification reactions in DAB microcompartments The DAB suspended in oil is subjected to temperature cycling in the same chamber on a Peltier element 30x30x4.7mm, 19.3W (Quick-Ohm, Kupper&Co. GmbH, no. QC-71-1.4-3.7M). When heated above 32°C, the DAB is concentrated such that the reaction mix inside the DAB is expelled. This forms a single aqueous droplet around the periphery of the concentrated DAB that serves as the micro-reaction compartment where the amplification of individual DNA molecules takes place.

[0218] PCR amplification is carried out for 40 cycles with the following parameters: Cycle 1: 95°C 5 min 65°C for 30 seconds 72°C for 30 seconds Cycles 2-40: 94°C for 30 seconds 65°C for 30 seconds 72℃ for 30 seconds.

[0219] After completing the amplification, the SYBR green signal of individual particles is detected by fluorescence microscopy. Data analysis is performed according to established algorithms for digital PCR.

[0220] Determining the optimal dynamic measurement range Non-specific binding of DNA label detection antibodies to DAB represents a key parameter that limits the applicability of digital immuno-PCR. Non-specifically bound labels result in false positive DAB after amplification. Therefore, in digital immuno-PCR, quantification of the analyte is achieved by determining the difference between the positive sample and the negative control.

[0221] In one extreme scenario, non-specific binding of the detection antibody may result in a large proportion of DABs having false positive signals in control reactions that do not contain analyte. This is mitigated by reducing the effective concentration of the detection antibody, either by gradually reducing the concentration of the detection antibody during the assay, or by maintaining the antibody concentration by increasing the dilution of the DNA-labeled detection antibody with the same antibody without the DNA label.

[0222] Example 8 Antigen Enrichment and Detection in Immunoassay Format Here we describe the enrichment and detection of antigens using sensor bodies according to the invention.

[0223] The sensor body ("bead") according to the invention, composed of the thermoresponsive polymer pNIPAM, offers the opportunity to enrich and detect antigens in combination with the ability to thermally cycle. Work with prototype beads made by the inventors has led to a simple one-step protocol with a labeled detection antibody, a streptavidin-labeled capture antibody, and biotinylated pNIPAM particles as the employed reagents. Figure 8 illustrates the principle of such an embodiment. All steps are carried out in a single reaction vessel ("container"), with no transfer steps required. When the reagents are mixed with EDTA-plasma containing the NS1-antigen and subjected to several cycles of thermal cycling (e.g. 40x[40°C-20°C], 10 s cycle time), efficient binding of the sandwich complex is achieved. This is explained by repeated swelling and contraction of the particles, which results in a substantial flow of material through the binding surface, ensuring effective capture from liquids in close proximity to the particles. This effect is supplemented, if necessary, by liquid movement by pumping the entire reaction mix back and forth in a chamber ("container", "reaction vessel") to achieve efficient macroscopic liquid exchange around each particle. Substantial signal increase is achieved when the particles are imaged in fluorescence in the contracted state (at temperatures above the lower critical solution temperature (LCST, e.g., 40°C), as shown in Figure 9. Images of fluorescent particles are shown at the optimal exposure setting of the detector, but the graph in the top panel of Figure 9 is normalized to an exposure time of 1 second. The detectable signal in the contracted state was found to be strong enough for most formulations to distinguish the particle-bound signal, indicative of analyte binding, from the background fluorescence caused by unbound fluorescent detection antibody.

[0224] To achieve mechanical agitation of the liquid sample in the container, a syringe pump was programmed to perform repeated transfers of the liquid incubated in the container, while a computer-controlled Peltier element was used for simultaneous temperature cycling.

[0225] Various particles / sensor bodies were synthesized according to different recipes 1-6 (indicated by numbers 1-6 just below the respective bars in the graph of FIG. 9). The particles differed with respect to the concentration of polymer, the type and concentration of comonomer, and the degree of crosslinking. More specifically, the composition of the particles / sensor bodies was as follows: [Table 19]

[0226] Even without elaborate optimization, the one-step immunoassay turned out to show excellent performance. Diluted samples of spiked NS1 serotype 2 from ICL were assayed with 01961-streptavidin as capture antibody and 1838-RPE as detection antibody. The assay is very fast and easy to perform (mixing all reagents with the sample) with a total assay time of about 4-5 min. As can be seen in Figure 10, EDTA-plasma spiked with antigen at a concentration of 2 ng / mL can be repeatedly and even clearly distinguished from the negative control sample (plasma without spiked NS1). No washing or transfer steps are required. Also shown is a negative control (sample without NS1 spike) where particles can barely be recognized but there is no measurable (fluorescent) signal. References [ka] [ka]

[0227] Further modifications of the preferred embodiments are possible without departing from the scope of the invention, which is defined solely by the claims.

[0228] The features of the invention disclosed in the specification, the claims and / or the accompanying drawings may be material for realizing the invention in various of its forms, both separately and in any combination thereof.

Claims

[Claim 1] The invention described in this specification.

Citation Information

Patent Citations

  • A method for isolating an analyte from a sample

    JP2009510442A